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3Abstract
During the third trimester of pregnancy, iron transport from mother to the
foetus against a concentration gradient determines the iron endowment in
foetal and neonatal life. Hfe functions as an upstream regulator of liver
hepcidin which has been demonstrated to be a negative regulator of intestinal
absorption of dietary iron and macrophage efflux of recycled iron. Hepcidin
has also been proposed to be a negative regulator of iron efflux from the
placenta, however it is not known if hepcidin is of maternal or foetal origin
during pregnancy. The exact mechanism and molecules involved in the
regulation of iron transport across the placenta are not well understood.
In this study the effects of Hfe and dietary iron levels on transfer of iron from
mother to foetus was investigated in order to determine the importance of
maternal and foetal Hfe status on iron transport. The effect of maternal
hepcidin on placental iron transport in WT and Hfe KO dams was also studied.
The molecular mechanism of iron transport across placenta was elucidated by
using BeWo cells as a model for iron uptake, transport and efflux.
This study has shown that the mechanism regulating iron metabolism during
pregnancy is dependent on the iron status of the mother and its genotype. A
clear link could be seen between the maternal iron status and foetal body iron
stores. The lack of Hfe in both dams and pups increased iron absorption in the
body and raised serum iron levels but the effect of Hfe was diet dependent.
4However, foetal genotype seems to affect liver iron accumulation and certain
iron transporter gene expression only with low and normal iron diets.
In this study BeWo cells were utilised to model the placental
syncytiotrophoblasts. The insensitivity of iron transporter proteins in BeWo
cells to hepcidin treatment might be due to the cell-specific response of
hepcidin. TfR1, DMT1 and FPN1 were localised in these cells to understand
the molecular mechanism of iron transport across placenta. Finally, the
presence of ZIP14 and its response to hepcidin treatment in mice may
indicate the presence of an alternative pathway of iron transport across
placenta.
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Chapter 1
General Introduction
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1.1 Biological importance of iron
Iron serves as an important catalytic centre in many enzymes as either
nonhaem iron-containing proteins or haemoproteins, which makes it crucial for
life. Haemoproteins are involved in wide ranging biological functions, including
oxygen binding (haemoglobins), electron transfer such as the electron transport
chain of mitochondria (cytochromes), and oxygen metabolism (oxidases,
peroxidases, catalases, etc.) (Winfield 1965). Nonhaem iron-containing proteins
like mitochondrial aconitase and iron-sulphur proteins of the electron transport
chain are involved in energy metabolism (Jordanov et al. 1992), whereas
ribonucleotide reductase is vital for DNA synthesis (Uppsten et al. 2004). Iron-
containing proteins are also required for the metabolism of catecholamines,
collagen, and tyrosine.
Iron exists in solution in two oxidative states, ferrous (Fe2+) and ferric form
(Fe3+), which can donate and accept electrons, respectively. In order to prevent
these redox reactions becoming hazardous for the organism, iron must be
either bound to protein or kept in the trivalent redox state (McCord 1998).
Therefore absorption, concentration, and the redox state of iron must be
carefully regulated to supply the appropriate amount of iron for growth and
survival while preventing iron deficiency or iron excess.
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1.2 Distribution of iron in the body
A normal adult male (70 kg) has a total body iron of about 4 grams, which
remains almost constant throughout adult life. Iron homeostasis in the body is
largely maintained by regulation of its absorption in the duodenum. After
absorption, it enters the circulation by binding to a serum protein, transferrin.
About 2.5 g of iron circulates in the red blood cells as haemoglobin which is
formed in bone marrow. A large part of iron is conserved by recycling from
haemoglobin of aged erythrocytes by reticuloendothelial macrophages. Liver
predominantly stores about 1 g of excess iron in the parenchymal tissue as
ferritin and hemosiderin. Approximately 0.3 g is integrated into respiratory
enzymes and myoglobin. 1 to 2 mg of iron is lost daily from an adult due to
minor bleeding, exfoliation of iron-containing epithelium of skin, gastrointestinal,
and urinary tract (Figure 1.1). However, women during childbearing years, lose
twice that amount due to menstruation and childbirth. Therefore, to maintain
normal iron balance in the body the same amount of iron from dietary sources
is required to replace the lost (Bothwell et al. 1979; Crichton 1991; Conrad and
Umbreith 2002).
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Figure 1.1 Schematic diagram showing iron distribution in the body
Iron is absorbed by the duodenum and enters the circulatory system by binding to
transferrin. Iron is incorporated into haemoglobin after being taken up by the bone
marrow and is recycled during the apoptosis of red blood cells by reticuloendothelial
macrophages. Myoglobin and various enzymes also utilise small amounts of iron for
their synthesis. Liver predominantly stores excess iron in the parenchymal tissues. 1-2
mg of iron is lost due to exfoliation of the epithelial lining of the gastrointestinal and
urinary tract, hair and skin and blood loss during menstruation. The human body does
not posses the physiological mechanism to excrete excess iron. Modified from
Andrews, 1999.
1-2 mg per day absorbed
in duodenum
Serum Transferrin
3 mg
Bone marrow
300 mg
RBCs
2300 mg
Reticuloendothelial
macrophages 600 mg
Storage in
Liver
1000 mg
1-2 mg per day of iron loss
Desquamation
Menstruation
Minor blood loss
Muscle
Myoglobin
300 mg
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1.3 Iron absorption, transport and storage
Iron homeostasis in the body is primarily maintained by duodenal iron uptake
depending on iron stores and its bodily requirements (Hallberg et al. 1997).
Dietary iron is present mostly in the Fe3+ form which is biologically unavailable.
This iron is reduced to Fe2+ before entering the duodenal enterocytes through
Divalent Metal Transporter 1 (DMT1) by the action of either reducing agents
(ascorbic acid, cysteine and histidine) or Duodenal cytochrome b (Dcytb)
(Andrew 1999; Mckie et al. 2001). Haem, present in diets from animal sources,
contributes about 30% of the total iron absorbed by the body. Haem is carried
into the cytosol of enterocytes through Haem Carrier Protein-1 (HCP1) and is
broken down by haem oxygenase (HO), subsequently liberating Fe2+ and
bilirubin (reviewed by Sharp and Srai 2007).
Iron is effluxed from the duodenal enterocytes into the circulation via ferroportin
1 (FPN1) and immediately oxidised to Fe3+ catalysed by either hephaestin in
the gut or ceruloplasmin in the plasma. Iron efflux is mainly a passive transport
against a concentration gradient (McGregor, 2006). In the circulation, iron is
bound to serum protein transferrin (Tf). In normal conditions, Tf is about 30%
iron-saturated and has a high iron-binding capacity to overcome damage
caused by the accumulation of non-Tf-bound iron (NTBI). However, in some
iron overload disorders like hereditary hemochromatosis, plasma iron levels
exceed Tf saturation capacity which results in high NTBI levels in plasma and
hepatic iron loading. The exact chemical nature of NTBI and its mechanism of
uptake by the cells are not known but ZIP14, a zinc transporter, is believed to
be involved in NTBI uptake (Liuzzi et al. 2006).
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Hepatocytes, developing erythroids, reticuloendothelial macrophages and
placental syncytiotrophoblasts acquire iron from plasma Tf. Diferric-Tf binds to
transferrin receptor (TfR) at the surface of these cells. This complex is
internalised via clathrin-coated pits to endosomes where iron is dissociated
from Tf in an acidic environment (Van Eijk & de Jong 1992). Iron is released
into the cytosol after reduction by probably six-transmembrane epithelial
antigen of prostate protein 3 (STEAP3) and transport by DMT1 present on
endosomal membranes. There are indications of alternative pathways of iron
transport from endosomes as it has been demonstrated that DMT1 knock out
(KO) mice can transport iron across placenta (Gunshin et al. 2005). Some
evidence has been found for the involvement of zinc and calcium transporters
in iron transport (Luizzi et al. 2006; Oudit et al. 2006), although the role of
calcium transporters is controversial (Ludwiczek et al. 2007; Mackenzie et al.
2010). Excess iron is stored in ferritin, a storage protein, in the form of Fe3+.
To maintain the plasma iron range of 10 to 30 µM, iron is effluxed into the
circulation via FPN1. The expression of FPN1 is confined to cells with a specific
iron efflux function i.e. placental syncytiotrophoblasts, duodenum,
macrophages, hepatocytes and brain endothelial cells (Rouault & Cooperman
2006). The systemic iron uptake, transport and storage are shown in Figure
1.2.
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Figure 1.2 Schematic diagram showing systemic iron uptake, transport and
storage
Dcytb present on the brush border membrane of duodenal enterocytes reduces iron
before it enters the cells via DMT1. In an alternative pathway iron as haem is taken up
by HCP1 transporter. Iron from both pathways enters the Labile Iron Pool (LIP) from
where the excess iron is stored in ferritin and the remainder is effluxed into the
circulation by the iron exporter FPN1 after oxidation by a MCF. Serum iron is bound to
Tf which is responsible for delivering iron to various tissues including hepatocytes
(major site of iron storage) and macrophages. Reticuloendothelial cells also take up
iron by engulfing senescent RBCs and breaking down haemoglobin to release iron into
the circulation or for storage in ferritin.
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1.4 Proteins involved in iron absorption, transport and storage
1.4.1 Transferrin
Transferrin (Tf) is a 76-80 kDa plasma glycoprotein that is responsible for the
transport of iron to and from various cells throughout the body (Ponka et al.,
1998). Each of the two homologous lobes of Tf (one on the amino-terminal
domain and the other on the carboxy-terminal domain) contains a high affinity
Fe3+-binding site. Diferric-Tf (also called holo-Tf) is taken up by many cells for
example liver, macrophages and placenta (Trinder et al. 1986; McArdle et al.
1985)
The affinity of iron for Tf is a pH-dependent process. In plasma, where the pH is
approximately 7.4, Tf binds iron very strongly, whereas virtually no binding
occurs at pH<4.5. This pH-dependent property plays an important role in the
physiological mechanism of release of iron from Tf (Anderson et al. 1989).
One of the functions of Tf is to direct iron to the cells (macrophages,
hepatocytes and placental syncytiotrophoblasts) that express transferrin
receptor and another function is to bind iron released from the cells thus
minimizing the amount of free iron in plasma and reducing the possibility of
toxic oxygen radical formation. Tf production increases with iron deficiency and
decreases with iron loading (McKnight et al. 1980).
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1.4.2 Transferrin receptors
Tf is recognized by specific cell membrane receptors that act as gatekeepers
responsible for physiological iron uptake by most cell types (Richardson and
Ponka, 1997). In addition to maintaining normal homeostasis in the body, these
molecules are required to sense iron concentration and communicate with the
circuitry that controls the production of hepcidin (negative iron regulatory
hormone). Transferrin receptor 1 (TfR1) and transferrin receptor 2 (TfR2) are
the two iron sensor proteins, which are expected to sense the extracellular
concentration of holo-Tf by conventional mechanisms dependent on receptor
occupancy.
1.4.2.1 TfR1
TfR1 is a 180 kDa disulphide-linked transmembrane glycoprotein homodimer
with each subunit (90kDa) binding one molecule of Tf (Kanevsky et al. 1997).
The binding affinity of TfR1 to diferric-Tf is 10-fold higher than monoferric-Tf
and 2000-fold higher than Apo-Tf (Tf without iron) at pH 7.4 (Watkins et al.
1992). The interaction of haemochromatosis-related protein, HFE with TfR1
decreases the affinity of TfR1 for Tf (Feder et al. 1998). There is a possibility
that TfR1 could function as an iron sensor (rather than a Tf uptake protein)
within a protein complex that includes HFE. Schmidt et al. (2008) recently
demonstrated the importance of the TfR1-HFE interaction for iron regulation by
introducing mutations into mice to strengthen or weaken the interaction
between HFE and TfR1. A mutation that caused an increase in HFE binding to
TfR1 resulted in hepcidin deficiency and iron overload. On the other hand mice
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with a mutation that interferes with the TfR1-HFE interaction or mice with higher
HFE content had high hepcidin and iron deficiency (Schmidt et al. 2008).
1.4.2.2 TfR2
TfR2 codes for at least 2 alternatively spliced transcripts: the alpha (α) form
approximately 2.9 kbp long (AF067864) and the beta (β) form, approximately
2.5 kbp long (AF053356). TfR2-α is a type II transmembrane protein with high
similarity to TfR1. TfR2-β lacks the amino terminal portion, which includes the
putative transmembrane domain and part of the extracellular domain. It is
therefore thought to be an intracellular form of receptor. The putative
extracellular domain of the TfR2-α protein is highly homologous to TfR1 and is
able to bind Tf and mediate iron uptake, although the binding affinity of holo-Tf
is lower for TfR2 than TfR1 (Kawabata et al. 1999).
An interaction between HFE and TfR2 has also been found (Chen et al. 2007)
but unlike the TfR1-HFE interaction, both Tf and HFE stabilise TfR2 (Johnson
and Enns, 2004). Few studies have shown iron overload caused by deficiency
of TfR2 in mice and humans (Fleming et al. 2002; Wallace et al. 2005). Also,
tissue specific ablation of TfR2 in liver resulted in iron overload (Wallace et al.
2007). TfR2 deficiency seems to regulate systemic iron by decreasing hepcidin
levels in mice (Kawabata et al. 2005; Wallace et al. 2005) and humans
(Nemeth et al. 2005).
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1.4.3 Divalent metal transporter 1
Ferrous iron, after reduction by Dcytb (a 286 amino acid protein with six
transmembrane domains providing binding sites for ascorbate and
dehydroascorbic acid which helps in reduction of ferric iron), is transported
across the duodenal brush border membrane by the divalent metal transporter
1 also known as natural resistance-associated macrophage protein 2 (Nramp2),
divalent cation transporter 1 (DCT1), and solute carrier family 11 membrane 2
(SLC11A2). DMT1 is a mammalian transmembrane proton-coupled metal-ion
transporter which mediates the transport of various divalent metal ions
including Fe2+, Cd2+, Co2+, Ni2 +, Cu2+, and Ca2+ but with its highest affinity for
iron (Gunshin et al. 1997).
Studies in Belgrade rats and microcytic mice (Fleming et al. 1997, 1998)
together with the ectopic expression studies (Griffiths et al. 2001) demonstrated
that DMT1 plays a vital role in intestinal iron uptake and endosomal iron
transport. The discovery of a DMT1 mRNA isoform with an iron-responsive
element (IRE) in the 3’ untranslated region accounts for its ability to maintain
iron homeostasis through regulation of its expression level in response to
dietary iron status, whereas the DMT1-IRE isoform, which lacks the IRE
domain, lacks this function (Lee et al. 1998). DMT1+IRE and DMT1-IRE differ
in their last C-terminal 18 or 25 amino acids and are found to have distinct
subcellular localisation and differential cell type specificity in the adult human
(Tabuchi et al. 2000). DMT1+IRE is predominantly expressed in epithelial cells
of duodenum that suggests its role as apical iron transporter while the
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expression of DMT1-IRE in erythroid precursor cells suggests that it is an
endosomal iron transporter.
1.4.4 ZIP14
In certain physiological conditions like hereditary haemochromatosis, iron
overload causes increased transferrin saturation (TFS) resulting in increased
non-Tf-bound iron (NTBI) in serum which is believed to be taken up by a
transmembrane protein, ZIP14 in hepatocytes (Gao et al. 2008; Liuzzi et al.
2006). Zrt-, Irt-like proteins (ZIP) are a group of protein transporters involved in
bio-metal transport into the cytosol of various cells. Mostly they are responsible
for zinc transport (Vallee and Falchuk 1993). Zinc transporters are divided into
four subfamilies, I, II, Gufa and LIV-1 (Liuzzi and Cousins 2004; Taylor and
Nicholson 2003). LIV-1 subfamily constitutes of members called LZT (LIV-1
subfamily of ZIP zinc transporters) which are part of solute carrier family 39
(slc39A) and are transmembrane proteins. It has been found that HFE
decreased ZIP14 levels in HepG 2 cells which resulted in less NTBI uptake
(Gao et al. 2008). The localisation of ZIP14 in iron transporter cells is not
known. There is a possibility of its involvement in alternative pathways of iron
uptake in cells as mice, in the absence of DMT1, were capable of transporting
iron to their foetus (Gunshin et al. 2005).
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1.4.5 Ferritin
Excess iron in the cytoplasm of cells is stored as ferritin, which is a ubiquitous
protein. Mammalian ferritin can accommodate up to 4500 atoms of iron in its
protein shell’s internal cavity. The protein shell has a molecular mass between
430 and 460 kDa and has 24 symmetrically related subunits of two types: a
light subunit (L-subunit) of approximately 19 kDa and a heavy subunit (H-
subunit) of approximately 21 kDa. The entry and exit of iron may occur via
channels in the protein shell. Inside the protein shell, iron is stored in the ferric
oxyhydroxide phosphate of approximate composition (FeOOH)8 (FeO-OPO3H2)
(Theil 1987; Harrison and Arosio, 1996). The origin and possible physiological
roles of ferritin other than iron storage in the body remain indefinable.
1.4.6 Ferroportin 1
Ferroportin 1 (FPN1), a 571 amino acid membrane protein, is also known as
metal transporter 1 (MTP1), iron regulated gene 1 (IREG1), solute carrier family
40 (iron-regulated transporters), membrane 1 (SLC40A1), and solute carrier
family 11 (proton coupled divalent metal ion transporters), membrane 3
(SLC11A3). FPN1 has a cytoplasmic amino acid membrane terminus and 10 to
12 transmembrane domains (Abboud and Haile 2000; McKie et al. 2000;
Donovan et al. 2000).
FPN1 is an iron exporter present on the basal membrane of absorptive
intestinal enterocytes, hepatocytes, macrophages, and placental cells, all of
which release iron into plasma (Abboud and Haile 2000; McKie et al. 2000;
Donovan et al. 2000). FPN1 as an iron exporter was proved by making it
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inactive in mice embryos which resulted in anaemic newborns with high iron
accumulation in duodenal enterocytes, hepatocytes and macrophages
(Donovan et al. 2005). This finding that FPN loss leads to severe anaemia in
newborn mice confirms its important role in placental iron transport.
FPN1 internalisation via tyrosine phosphorylation followed by ubiquitination and
degradation is regulated by hepcidin (Nemeth et al. 2004; De Domenico et al.
2007). Cellular iron levels also regulate FPN1 mRNA and protein expression.
Changes in FPN1 expression are mediated by transcriptional and translational
mechanisms. Translational regulation involves a 5’ iron regulatory element
(IRE) located in FPN1 mRNA (Liu et al. 2002).
1.4.7 Multicopper ferroxidases
Ceruloplasmin (Cp), Hephaestin (Heph) and the newly identified Zyklopen (Zp)
are multicopper ferroxidases (MCF) (Kosman 2002; Vulpe et al. 1999; Chen et
al. 2010). These MCFs are believed to be involved in maintaining iron
homeostasis by oxidising it to the Fe3+ form, the latter is taken up by Tf as
described in Section 1.4.1 (Kosman 2002; Anderson and Vulpe 2009).
An absence of Cp, has shown decreased cellular iron efflux via degradation of
FPN1 in some cells (De Domenico et al. 2007). Duodenal enterocytes express
Heph and its mutation has resulted in more iron accumulation in duodenum and
an anaemic body (Vulpe et al. 1999). Liver predominantly produces Cp, which
is a serum protein and its mutation has caused higher iron accumulation in
multiple tissues leading to serious consequences (Harris et al. 1999). These
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findings have confirmed the importance of MCFs in the regulation of iron
transport. A recent study has proposed the presence of a novel MCF in
placenta, which is structurally similar to Heph, called ZP (Chen et al. 2010). Its
presence in other tissues is not known.
1.5 Iron homeostasis during pregnancy
During pregnancy duodenal iron absorption increases to compensate for the
increase in foetal iron accumulation (Whittaker et al. 1991). Iron deficiency
anaemia during pregnancy is one of the major causes of mortality and morbidity
in pregnant women taking the lives of about half a million women each year
(WHO 1991; 1992). Low maternal iron status also results in increased still
births, preterm delivery, low birth weight babies, severe foetal growth
retardation, long term problems including increase in blood pressure (Crowe et
al. 1995), supressed immune system development (Luckwood & Sherman
1988) and diminished brain function (Soewondo 1995).
The World Health Assembly passed a resolution in 1992 urging its 90 member
countries to adopt measures against iron deficiency in pregnant women by
providing iron supplementations. It is surprising that sometimes these
supplementations cannot overcome deficiency. A newborn infant derives 250
mg of iron from maternal iron stores via the placenta (Conrad & Umbreit 2002).
During pregnancy, about 1 g of iron is lost from the mother due to expansion in
maternal blood volume and transport of the metal to the foetus. The amount of
iron transferred across placenta increases as gestation progresses but how this
is mediated is unknown. At first, the placenta was thought to be responsible for
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iron regulation during pregnancy but recent data suggested that this is a
complex mechanism which might involve foetal and maternal livers. HFE and
hepcidin are thought to be the central iron regulatory proteins involved in body
iron homeostasis.
1.5.1 Placenta and its functions
The intimate relationship between the embryo and mother is one of the most
important features of human embryonic development. During intrauterine life
the survival and growth of the fertilised egg depends on the mother. The
placenta surrounds the embryo and serves as the interface between the
embryo and mother. The major role of the placenta is to provide nutrients and
oxygen to the foetus and to eliminate foetal waste products and carbon dioxide.
It synthesises and secretes hormones, growth factors, cytokines, and other
bioactive molecules. It also protects the foetus against pathogens and forms an
immunological barrier between mother and foetus (Pepe and Albrecht, 1995;
Schneider 1991). For maintaining pregnancy and promoting normal foetal
development, these comprehensive activities are essential.
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1.5.2 Anatomy of the placenta
The placenta, a foetomaternal organ, consists of a foetal and a maternal part. A
foetal portion develops from the chorionic sac. The chorionic sac constitutes the
outermost foetal membrane in the human embryo and its villous part makes the
foetal portion. On the other hand the maternal portion is derived from the
endometrium, which makes the lining of the uterus. The cytotrophoblastic shell,
an external layer of foetally derived trophoblastic cells, attaches the foetal and
maternal portion of the placenta (Moore and Persaud 1998).
Until 20 weeks of pregnancy, the placental membrane consists of four layers:
syncytiotrophoblasts, cytotrophoblasts, connective tissue of villus, and
endothelium of foetal capillaries. After 20 weeks, due to histological changes,
cytotrophoblast cells start disappearing over large areas of villi and leaves
syncytiotrophoblasts in thin patches. At this stage the placenta consists of three
layers instead of four. The placental membrane becomes markedly thin in some
areas as the pregnancy progresses and syncytiotrophoblasts come in direct
contact with foetal capillaries forming the vasculosyncytial placental membrane.
Most of the nutrients and gases are transported from maternal serum to foetal
serum through the placental membrane (Moore and Persaud 1998).
40
1.5.3 Comparison between human and mouse pregnancy and
placentation
Established laboratory rodents such as mice, rats and rabbits have the
advantage of short gestation times during pregnancy and large litters. Human
and mice placental structure and pregnancy have some similar features. In
mouse placenta, many cell types are analogous to those in human placenta, for
example proliferating trophoblastic cells, invasive trophoblasts and cells
differentiating into syncytium (Rossant and Cross 2001). Haemochorial
plancenta, where maternal serum directly irrigates the foeto-placental
epithelium, is common in both (Rossant and Cross 2001). A further comparison
is shown in Table 1.1, taken from Carter, 2007.
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Table 1.1 Comparison of human and mouse pregnancy and placentation
Mouse Human
Gestation Three weeks Nine months
Implantation Secondarily interstitial Primarily interstitial
Yolk sac Inverted yolk sac placenta
functions to term
Yolk sac floats free in
exocoelom during first
trimester
Trophoblast invasion
of uterine arteries
Shallow; limited to proximal
decidua
Extensive; reaching
myometrial vessels
Transformation of
uterine arteries
Dependent on maternal
factors (uterine natural killer
cells)
Dependent on
trophoblast
Placental exchange
area
Labyrinthine Villous
Interhaemal barrier Three trophoblast layers;
outer one cellular, inner two
syncytial
Single layer of syncytial
trophoblast
Placental hormones Placental lactogens Chorionic gonadotropin,
placental growth
hormone; major source
of progesterone
Taken from Carter (2007)
1.5.4 BeWo cells
To study the cellular activities and transplacental transport processes BeWo
cells serve as a valid and convenient system (Taylor et al. 1991). The BeWo
cell line originated from a human choriocarcinoma, a monolayer-forming
trophoblast cell line with the capacity to differentiate into a syncytium (Pattillo &
Gey 1968) and can be grown on filters for studying transport of iron in vitro.
These cells differ from other polarized epithelia in that they mediate
unidirectional iron transport in an apical to basal (i.e. maternal to foetal)
direction via Tf and TfR1 at the apical membrane (Turkewitz & Harrison 1989).
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These cells secrete placental hormones, including gonadotrophin, lactogen and
steroid hormones (Cerneus & Van der 1991). These cells have been used
previously as an in vitro model to study glucose ((Vandhana & Illsley 2002),
amino acids (Eaton & Sooranna 1998; 2000) and iron (Danzeisen & McArdle
1998; Van der Ende et al. 1987) transport across placenta.
1.6 Mechanism of iron transport across placenta
Buus and Boockfor in 2004 investigated the production of TfR by several
placental cell lines, Rch0-1 (rat trophoblastic Giant cells), HRP-1 (rat labyrinth
syncytial cells), and BeWo cells. In species with a haemochorial placenta, it has
been demonstrated that maternal iron attached to Tf binds TfR1 on the brush
border membrane of the placenta which is then internalised in endosomes
within the cell. Iron is subsequently released from Tf in the endosome and
enters the cytoplasm while Tf and TfR1 are recycled back to the cell surface,
which means Tf does not cross the multiple cell layer barrier of the placenta
(McArdle et al. 1985). TfR1 is expressed more on syncytiotrophoblasts (STB)
than on cytotrophoblasts. It has been localised on both the apical and basal
membranes of the STB (Vanderpuye et al. 1986) but its role on the basolateral
surface is not known.
HFE is also expressed in coated pits on the apical side of syncytiotrophoblasts
where it is believed that it forms a complex with TfR1 and β-2-microglobulin
(Parkkila et al. 1997). Contrary to this, Bastin et al. in 2006 found HFE on some
parts of the basal membrane of syncytiotrophoblasts in large amounts where
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FPN1 protein is strongly expressed. There is very little data on the role of HFE
and hepcidin in the regulation of iron transport across the placenta.
In placental tissue, DMT1 is perceived to take part in the traffic of divalent metal
ions. In human placenta at birth, DMT1 has been shown
immunohistochemically to localise to the cytoplasm and basal membrane of
syncytiotrophoblasts, which led to the supposition that the transport of ferrous
iron from endosome to the cytoplasm, as well as across the basal membrane,
is mediated by DMT1 (Georgieff et al. 2000). Gunshin et al. (2005)
demonstrated that DMT1 is not essential to deliver iron to the foetus. They
showed that DMT1 KO mice were born anaemic but the total iron content in the
new born pups was similar to WT. They also demonstrated that the liver in the
DMT1 KO mice had higher levels of iron than WT mice. This strongly suggests
that alternative pathways of iron transfer exist in the placenta. By contrast,
following birth, the DMT1 KO mice died of iron deficiency quite rapidly,
demonstrating that the protein is essential for iron absorption across gut.
Whether and how it is involved in the placenta is unclear and also information
regarding DMT1 expression in the placenta during early pregnancy is lacking.
The proposed model of iron transport by syncytiotrophoblast is shown in Figure
1.3.
Although the proteins involved in transport of iron across the
placenta have been identified, the mechanism and regulation of iron transport
in response to iron deficiency, overload and genetic variations, is not well
understood.
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Figure 1.3 Proposed model of iron transport by human syncytiotrophoblast
TfR1 present on the apical mambrane of STB binds maternal diferric transferrin and
forms a complex. This complex is internalised as an endosome which releases iron
from transferrin in the acidic environment in the ferrous form. This release allows
transfer of iron to the cytoplasm through DMT 1 which is localised intracellularly and
on the basolateral membrane of the syncytiotrophoblast cell. The mechanism of iron
release from transferrin and transfer to the cytoplasm via DMT1 is not clearly
understood. From the cytoplasm, ferrous iron moves into the intracellular transfer and
efflux pathway via FPN1 on or near the basolateral membrane of placenta. Before
release, iron is oxidised to Fe3+ probably by an MCF. A few studies have shown HFE
and DMT1 on the basolateral side.
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1.7 Hepcidin
Human hepcidin is a 25 amino acid antimicrobial peptide belonging to the
defensin family. It was first identified in human urine by Park et al. in 2001 who
named it hepcidin, based on its site of synthesis (the liver, hep-) and
antibacterial properties in vitro (-cidin). Krause et al. in 2000 independently
isolated it from plasma and named it LEAP-1 (liver-expressed antimicrobial
peptide). The main cellular sources of hepcidin are the hepatocytes but few
studies have shown its synthesis at a lower level by bacteria-activated
neutrophils and macrophages (Krause et al. 2000; Park et al. 2001). The
hepcidin gene has also been identified in mice, rats, pigs, dogs, and several
species of fish. Two other forms of this peptide are the 20- and 22- amino acid
forms but only the 25- amino acid hepcidin is shown to be biologically active.
The bioactive 25-amino acid form of hepcidin has a simple hairpin structure
with 8 cysteines that form 4 disulphide bonds in a ladder-like configuration. One
of the disulphide bonds is an unusual vicinal bond between adjacent cysteines
at the hairpin turn (Hunter et al. 2002). In a recent study, it was revealed that
the N-terminus of hepcidin is essential for its bioactivity (Nemeth et al. 2006).
Like other defensin peptides, it uses a relatively rigid antiparallel β-sheet
constrained by disulphide bonds as the framework, around which segregated
patches of cationic and hydrophobic residues are organised.
In humans, the HAMP gene produces hepcidin by encoding an 84-amino acid
preprohepcidin. This prepropeptide is cleaved to give the 60 amino acid form of
prohepcidin which is further cleaved to give the 25 amino acid form of hepcidin
46
that is found in blood and urine. The human HAMP gene comprises three
exons and maps to the long arm of chromosome 19 (19q13) (Park et al. 2001).
1.7.1 Role of hepcidin in iron metabolism
Pigeon et al. in 2001 were the first to study the connection between hepcidin
and iron metabolism during studies of the hepatic responses to iron overload.
They showed that the mRNA for hepcidin was overexpressed by hepatocytes of
experimentally iron-loaded mice. The upregulation of hepcidin was temporary
and reached a plateau as early as 2 months and 1 week in carbonyl iron and
iron-dextran overload model, respectively (Pigeon et al. 2001). It was proposed
that the transcription factor C/EBPα is involved in this iron-mediated increase of
hepcidin gene expression (Courseland et al. 2002). However, so far, the
mechanisms involved in this regulation remain to be elucidated.
1.7.2 Hepcidin deficiency
The specific role of hepcidin was demonstrated by the effects of hepcidin
deficiency or overload in transgenic mouse models. Mice made deficient for the
transcriptional factor USF (Usf KO mice) were found to have
haemochromatosis with iron deposition in the liver and pancreas while the
spleen of these mice was relatively protected from this iron loading (Nicholas et
al. 2002). This phenotype of mice indicated that hepcidin controlled intestinal
iron uptake and the retention of iron in macrophages. In Usf KO mice, iron
overload was similar to that observed in human hereditary haemochromatosis
and in Hfe KO mice, with increased iron circulation in the blood, increased
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transferrin saturation, decreased reticuloendothelial iron, and normal
haematological indices (Zhou et al. 1998).
The identification of two human families with severe juvenile haemochromatosis
with hepcidin deficiency managed to dispel doubts about the essential role of
hepcidin in iron homeostasis (Roetto et al. 2003). Each affected family member
had distinct homozygous destructive mutations in the hepcidin gene.
1.7.3 Hepcidin excess
The effects of hepcidin excess in mice that overexpressed hepcidin-1 were
shown under the control of a liver-specific promoter (Nicholas et al. 2002). The
newborn mice with hepcidin excess were born severely anaemic which may
indicate that foetal hepcidin inhibited the placental transport of iron to the
developing foetus. Excessive hepcidin also reduces intestinal iron uptake as
shown by the dependence of surviving mice on parenteral iron injections.
These findings are enough to indicate that hepcidin is a negative regulator of
iron transport in the small intestine and in the placenta and that it induced iron
retention in (mainly splenic) macrophages engaged in the recycling of iron from
senescent erythrocytes by targeting FPN1. Synthetic 25-amino acid hepcidin is
responsible for hypoferremia in mice, and if injected it can decrease serum iron
levels up to 75% within 1 hour and the effect can persist for more than 48 hours
(Rivera et al. 2005). Figure 1.4 represents the schematic diagram showing the
interaction of hepcidin with FPN1 to control iron flow into the circulation.
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Figure 1.4 Schematic diagram showing the interaction of hepcidin with FPN1 to
control iron flow into the circulation
Hepcidin controls systemic iron homeostasis by interacting with FPN1. Hepcidin
targets the FPN1 present on duodenal enterocytes responsible for iron absorption,
macrophages involved in the recycling of iron from dying RBCs and iron storage organ
(liver). The FPN1 degradation results in less iron inflow into the circulation. During
pregnancy, foetal hepcidin controls iron transport across placenta. Modified from Ganz
2011.
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1.8 HFE as an iron regulator
The HFE protein is a 343 amino acid protein, homologous to the major
histocompatibility complex (MHC) class I-like glycoproteins consisting of 3
extracellular loops (α1, α2, and α3), a transmembrane region and a short
cytoplasmic tail (Waheed et al. 1997). This protein is predominantly expressed
in liver hepatocytes and is also found in intracellular and perinuclear
compartments in the enterocytes of duodenal villus crypts (Parkkila et al.
1997a). It is also highly expressed in placental syncytiotrophoblasts (Parkkila et
al. 1997b). The expression of HFE has profound effects on cellular iron status.
Haemochromatosis due to mutations in the HFE gene is characterised by
inappropriate high iron absorption and reticuloendothelial cell release that
results in excess iron entering the circulation and subsequent deposition in
parenchymal cells such as hepatocytes. While the precise function of the HFE
protein is unknown, recent studies have shown that mutations in the HFE gene
results in an inappropriately low level of hepcidin expression (Ahmad et al.
2002). The decrease of circulating hepcidin leads to an increased ferroportin-
mediated iron efflux from reticuloendothelial cells and duodenal enterocytes
resulting in increased circulating iron and eventually the saturation of Tf.
Moreover, when Hfe KO mice were crossed with mice over-expressing
hepcidin, their overload status was normalised (Nicholas et al., 2003). These
studies suggest that HFE participates in the regulation of intestinal iron
absorption by modulating hepcidin expression (Mura et al., 2004).
However, there are difficulties in distinguishing the primary effects of HFE on
cellular iron status and its secondary effects resulting from changes in hepcidin
50
expression. Hepcidin mRNA measurements in patients with HFE-related
haemochromatosis and Hfe KO mice suggest that partial hepcidin deficiency
may contribute to iron overload in the most common form of haemochromatosis
(mutation in HFE gene).
1.9 Aims
The mechanism underlying maternal-foetal iron homeostasis is not clearly
defined. This study was carried out to determine the role of HFE and hepcidin
in iron transport across the placenta. The aims of this study are:
(1) To determine the role of maternal and foetal Hfe status and its down stream
modulator, hepcidin, in the transfer of iron across the placenta in vivo.
(2) To elucidate the molecular mechanism of iron transport across the placenta
using BeWo cells as a model for iron uptake, transport and efflux.
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1.10 Objectives
(1) To determine the effect of maternal Hfe status on iron transport across the
placenta when the foetal genotype is heterozygous.
(2) To determine the effect of foetal Hfe status on the transport of iron across
the placenta when maternal genotype is heterozygous.
(3) To determine the effect of dietary iron levels on maternal iron levels and
placental protein and gene expression of iron transporters
(4) To determine the effect of synthetic hepcidin on maternal iron status and its
effect on placental iron gene expression
(5) To use BeWo cells as a model of placental cells:
(i) To quantify iron transporter proteins’ and regulatory genes’ expression.
(ii) To determine the cellular localisation of iron transporter proteins.
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Chapter 2
Materials and Methods
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2.1 Mice strain, tissue collection and storage
All experimental procedures were approved and conducted in accordance with
the UK Animals (Scientific Procedures) Act, 1986. Mice (129/Ola-C57BL/6
mixed background strain) with a 2kb pgk-neo gene flanked by loxP sites
replacing a 2.5kb BglII fragment (for details see Bahram et al. 1999) were used
as Hfe knockouts (KO). Hfe KO mice were mated with wildtype (WT) mice to
produce heterozygotes (HET). For the experiments mentioned in Chapter 3,
mice of all three genotypes were used.
To determine the effect of maternal and foetal Hfe status on iron transport
across placenta mice were fed a high iron diet (150 ppm iron) for one week
after weaning. After one week, mice were placed on low (12.5 ppm),
normal/adequate (50 ppm) and high (150 ppm) iron diets. WT, HET and Hfe
KO females were mated with HET males three weeks later and remained on
their respective diet throughout pregnancy. Pregnancy was confirmed by
detection of a vaginal plug and this day was denoted day 0.
For the experiments mentioned in Chapter 4, only WT and Hfe KO mice were
used. After weaning, mice were fed RM1 (150 mg Fe/kg diet) for two weeks
followed by mating with males of corresponding genotype (WT or Hfe KO). On
day 14 of gestation, females were injected with either 0.15 M NaCl or 10 µg
hepcidin dissolved in 0.15 M NaCl via the intraperitoneal route. They were then
injected every 24 hours till day 18 of gestation.
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On day 18 of gestation, dams from each group were anaesthetised with
pentobarbitone. The foetuses were delivered by caesarean section and killed
by decapitation. Foetuses were weighed before dissection. Mice and foetal
tissues were collected by Dr. S. Balesaria, Royal Free Hospital, UK. After
collection, tissues were snap frozen in liquid nitrogen and stored at -80oC until
used.
2.2 Cell Biology
2.2.1 BeWo cell culture
Clone b30 of BeWo cells were incubated at 37oC with 5% CO2 in 75 cm2 flasks
(Nunc, Roskilde, Denmark) in 20 ml of Dulbecco’s Minimal Essential Medium
(DMEM) with Glutamax 1 (Invitrogen, Paisley, UK) supplemented with 10%
(v/v) gamma irradiated foetal bovine serum and 1% (v/v) antibiotic/antimycotic
(Invitrogen, Paisley, UK). Cells were sub-cultured after every 3-5 days when
they were 80% confluent and the medium was changed every 2 days.
2.2.1.1 Sub-culturing of BeWo cells
The medium was removed and the cells were washed with 10 ml prewarmed
Dulbecco’s Phosphate Buffer Saline (DPBS) (Invitrogen, Paisley, UK) twice. 5
ml of 1x trypsin EDTA (Invitrogen, Paisley, UK) was added to the cells and
incubated for about 5 min or until the cells were detached from the surface of
the flask. 10 ml of complete medium was added to resuspend the cells and
deactivate the trypsin. This cell suspension was transferred to a 15 ml Falcon
tube followed by centrifugation for 3 min at 2000 rpm at room temperature. The
supernatant was discarded and the cell pellet was resuspended in 10 ml of the
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complete medium and the aggregates were dispersed by pipetting the cell
suspension up and down several times. The appropriate amount of cells was
added to the fresh flask containing 15-20 ml medium (composition of medium is
mentioned in Section 2.2.1).
2.2.1.2 Cryopreservation of BeWo cells
BeWo cells (80% confluent) were trypsinised by 1x trypsin-EDTA and
resuspended in a complete medium at a density of 3 x 106 cells/ml. The cell
suspension was first cooled on ice before dimethylsulphoxide (DMSO) (Sigma,
Ayrshire, UK) was added to give a final concentration of 10% (v/v). A 1 ml
aliquot of the suspension was transferred to a sterile vial. The vial was frozen at
-80oC for 24 hours followed by storage in liquid nitrogen.
2.2.1.3 Recovery of frozen cells
A vial of frozen BeWo cells was taken out from the liquid nitrogen container. It
was thawed in a water bath at 37oC and disinfected with 70% ethanol. The
thawed cells were transferred to a tissue culture flask containing sufficient
medium to dilute the DMSO at least 10 fold. Cells were incubated as mentioned
in section 2.2.1 and the medium was changed after 24 hours to remove the
dead cells.
2.2.2 Culture of BeWo cells stably transfected with HFE
BeWo cells stably transfected with HFE were generated by Dr. H Bayele.
mRNA expression of HFE in these cells showed higher expression of HFE as
compared with normal BeWo cells. These cells were cultured with complete
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medium with 200 µg/ml of Zeocin and sub-cultured as explained in section
2.4.1 and its sub-sections.
2.2.3 HEK293 Tet-On and Tet-Off cell culture
HEK293 Tet-On hFPN1-Green Fluorescent Protein (GFP) cells (HEK293 with
pLVX-Tight-Puro lentiviral vector) were grown in DMEM supplemented with
10% tetracycline-free foetal bovine serum (Invitrogen, Paisley, UK), 100 µg/ml
G418, 0.5 µg/ml puromycin, 100 μg/ml penicillin, and 100 μg/ml streptomycin.
To turn on the hFPN1-GFP expression, the cells were seeded in a 6-well plate
and incubated with the supplemented medium containing 100 ng/ml of
doxycycline for 24 hours. Doxycycline was removed and the cells were treated
with 1 µM hepcidin for 12 to 24 hours before analysing the relative hFPN1-GFP
expression by FACS.
HEK293 Tet-Off hFPN1-GFP cells (HEK293 stably transfected with pTRE-Tight
vector) were grown with the supplemented medium containing doxycycline in a
6-well plate. Doxycycline was removed for 48 hours to turn on hFPN1-GFP
expression followed by replacement of medium with supplemented medium
containing doxycycline. The cells were treated with hepcidin for 24 hours and
analysed by FACs. Both cell lines were provided by Dr T. Ganz and Dr. E.
Nemeth, UCLA, USA.
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2.2.4 Cell counting with haemocytometer
BeWo cells were trypsinised with 5 ml of 1x trypsin EDTA before resuspending
the cell pellet in 10 ml of the medium and the aggregates were dispersed by
pipetting the cell suspension up and down several times to get the
homogenised cell suspension. A drop (20 µl) of cell suspension was placed on
the sample introduction point on the haemocytometer. Cells were counted in
four 1 mm squares grid using 400 x magnifications under inverse phase light
microscope (Axiovert 25, Zeiss, Germany) using push button counter. The
average value was calculated and it was multiplied by 1 x 104 to determine the
number of cells per cubic millimetre.
2.2.5 Transepithelial electrical resistance measurements
A TEER voltohmmeter along with STX-2 electrodes (World Precision
Instruments, Hertfordshire, UK) quantitatively assesses the confluence of a
cellular monolayer by measuring the total resistance across the cell culture
insert (Nunc, anopore, USA). The BeWo cells were grown on the anopore
inserts and the TEER was measured daily from the 3rd day of seeding until
confluence was achieved. For measuring the resistance, the inner electrode of
the STX-2 electrodes was inserted carefully into the insert to avoid damage to
the cell layer. The outer electrode was inserted into the cell culture well to touch
the bottom of the dish containing external culture medium, as shown in Figure
2.1. The STX-2 was connected to the EVOM meter to obtain the resistance.
Then the Blank reading/ resistance (Rblank) was subtracted from the total
resistance reading (Rtotal) across the monolayer in order to obtain the true cell
monolayer resistance (Rtrue cell).
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R (true cell) = R (total) – R (blank)
However, the unit area resistance was obtained by multiplying the true cell
resistance with the effective surface area of the insert.
Resistance of unit area = R (true cell) (Ω) x Effective insert area (cm2)
Resistance of unit area = R (true cell) x πd2/4
Figure 2.1 Schematic diagram showing the set-up of the STX electrode used to
measure TEER of BeWo cells
BeWo cells were grown on the anopore inserts at the density of 40 x 104 cells per well.
After three days post seeding, TEER was measured by electrodes and the reading
was recorded on the EVOM meter. The inner electrode of the STX-2 electrodes was
inserted into the insert and the outer electrode was inserted into the cell culture well to
touch the bottom of the dish containing culture medium. The resistance was measured
with the formula given in section 2.2.5.
Insert
Cell culture medium
Inner electrode
Outer electrode
Well of 6/24 well plate
Apical side of BeWo cells
Basolateral side of BeWo cells
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2.2.6 Treatment of cells with hepcidin
BeWo cells were grown on anopore inserts at the density of 40 x 104 cells per
insert for seven to ten days. The confluency of the cells was confirmed by
TEER measurement. 24 hours prior to treatment, the complete medium was
replaced by foetal bovine serum-free medium. Cells were treated with 1 µM
commercial or in house hepcidin (structure discussed in section 2.3.5) from 2,
4, 6, 8, 12 and 48 hours. After the treatment the medium containing hepcidin
was removed and the cells were washed with PBS three times and collected for
RNA or protein extraction. HEK293 Tet-On and Tet-Off cells were grown in 6-
well plates and treated as mentioned above.
2.2.7 Supplementation with iron (Fe-NTA)
0.024 g of FeCl3.6H2O was dissolved in 50 ml of 10 mM NTA (0.25 g NTA in
100 ml balance salt solution). The pH was adjusted to 7.4 with HCl and the
solution was sterile filtered. When the density of cells reached 70 to 80%
confluence, cells were subjected to 100 μM ferric nitriloacetic acid (Fe-NTA) for
48 hours followed by washing with DPBS twice before collection for total RNA
and protein extraction.
2.2.8 Induction of iron deficiency with DFO
BeWo cells were seeded in 6-well plates at a density of 40 x 104 cells until the
confluency reached 70%. Cells were subjected to 20 µM desferrioxamine
(DFO) for 40 hours to induce iron deficiency. Before collection for RNA
extraction, cells were washed with DPBS twice after the treatment.
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2.2.9 Fluorescence activated cell sorting (FACs)
HEK293 Tet-On and Tet-Off cells were cultured in 6-well plates and treated
with 1 µM hepcidin as described in section 2.2.3 and 2.2.6. After the treatment,
cells were washed with DPBS twice and trypsinised to detach them from the
plate. The cell suspension was centrifuged at 2000 rpm for 2 min at 4oC. The
cell pellet was resuspended in ice cold DPBS with the adjustment in cell
suspension to a concentration of 1 x 106 cells/ml. For the negative control,
hFPN1-GFP expression was turned off in both cell lines and in the positive
control it was turned on. Data was acquired by FACs using Beckman-coulter
CyAn ADP Flow cytometry with Summit v4.3 software and presented as
Mean+SEM in bar graph. (a) (b)
Figure 2.2 SSC vs FSC dot plot and GFP count plot of HEK293 Tet-On and Tet-
Off cells
(a) represents side scatter count (SSC) vs forward scatter count (FSC) dot plot. Each
dot represents a cell. Cell debris, cell aggregates and dead cells are labelled in the
plot. All the dots within the enclosed area represent normal and healthy cells. (b)
represents GFP count with more GFP expressed cells present in the second histogram
shown under R2 region as compared with negative control cells.
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2.2.10 Determination of intracellular distribution/localization of iron
transporter proteins by confocal microscopy
2.2.10.1 Fixation of BeWo cells with 4% paraformaldehyde
BeWo cells were routinely cultured at the density of 40 x 104 cells per coverslip
until they reached 60 to 70% confluency and fixed with freshly prepared 4%
paraformaldehyde for 30 min at room temperature. After fixation cells were
washed twice with PBS for 10 min by gentle shaking. Then the cells were
permeabilised with ice cold methanol/ethanol (v/v) for 5 min on ice followed by
two washings with PBS for 10 min and final wash with washing buffer (PBS and
0.1% BSA). Cells were incubated with blocking buffer (PBS and 1% BSA) for
20 min at 25oC. After washing with PBS twice the cells were stained with 1:100
dilution of anti-TfR1 (Santa Cruz, California, USA) for 2 hours at 25oC followed
by three washings with PBS for 10 min each. Cells were incubated with 1:1000
diluted secondary antibody coupled to Alexa488 (Invitrogen, UK) for 1 hour at
25oC. To stain the cell membranes, the cells were incubated with WGA-
Alexa594 (1:200 dilution) (Invitrogen, UK) for 15 min at 25oC followed by
washing with PBS twice and fixing on slides with mounting solution.
The slides were observed using a confocal microscope (Leica, TCS Sp5 AOBS,
Leica, Mannheim, Germany or Zeiss). For FITC and Alexa 488, a laser at 488
nm was used and emission collected from 498-548 nm. Every experiment was
performed, acquired and analysed similarly and each duplicate experiment
repeated three times.
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2.2.10.2 Fixation of cells with methanol
BeWo cells were plated at 70% confluence on coverslips. For anti-DMT1 and
anti-FPN1 staining cells were fixed with 100% methanol on ice followed by
immediate incubation for 3 min at -20oC. Cells were washed twice with PBS for
10 min at 25oC with gentle shaking followed by permeabilisation with PBS and
0.025% saponin for 40 minutes at 25oC and blocking with blocking buffer (PBS,
1% BSA and 0.025% saponin) at 25oC. Cells were stained with 1:100 diluted
anti-FPN1 (provided by Dr, G Anderson, Australia), anti-HFE (provided by Dr,
H. Drakesmith), anti-ZIP14 (provided by Dr. Knutsen, Florida, USA), anti-DMT1
(provided by Dr, G Anderson, Australia) or double stained with 1:50 dilution
anti-Nranp1 (Santa Cruz, California, USA) with anti-ZO-1, anti-Occludin or anti-
E-Cadherin (1:100) overnight at 4oC in a humidified chamber. After washing
twice with PBS they were stained with secondary antibodies (1:1000 dilution)
coupled to Alexa488 or Alexa594 (Invitrogen, UK) and mounted on slides.
The slides were observed using a confocal microscope (Leica, TCS Sp5 AOBS,
Leica, Mannheim, Germany or Zeiss). For Alexa 594, a laser at 594 nm was
selected and emission was collected from 605-751 nm. Each colour was
acquired sequentially. Every experiment was performed, acquired and analysed
similarly and each duplicate experiment repeated three times.
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2.3 Protein analysis
2.3.1 Crude membrane preparation
50 to 100 mg of tissue or cell samples were homogenised with lysis buffer
using mortar and pestle. The homogenised samples were centrifuged at 2500
rpm for 15 min at 4oC to get rid of cell debris. Supernatant was transferred into
a fresh tube and was centrifuged at 10,000 rpm for 45 min at 4oC. Supernatant
was discarded and the membrane pellet was dissolved in sucrose buffer and
stored at -80 oC. The crude membrane samples were used for western blotting
or immunoprecipitation.
2.3.2 Western Blotting
2.3.2.1 Sample preparation
30 to 40 µg of protein from tissue or cell samples was mixed thoroughly with an
equal volume of 2x Laemmli treatment buffer containing 0.125 M Tris-HCl
buffer with pH 6.8, 4% SDS, 20% (v/v) glycerol, 0.2 M dithiothreitol DTT, and
0.02% bromophenol blue with the pH adjusted to 6.8. The mixture was heated
at 95oC for 5 min then placed on ice before loading onto the gel. The SDS used
in the treatment buffer is an anionic detergent that wraps around polypeptide
backbone and denatures protein. In doing so, it confers a net negative charge
to the polypeptide in proportion to its length.
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2.3.2.2 Gel loading and transfer to the blot
The well forming comb was gently removed from the gel cassette and the wells
were rinsed with 1x tank/running buffer (Sigma, St. Louis, USA). Protein marker
(Biorad, USA) and samples were loaded carefully in each well. The upper and
lower chambers of the electrophoresis tank were filled with tank buffer and the
gel was run for approximately 90 min at 150 mA using a power pack (Biorad,
USA). Meanwhile polyvinylidine difluoride (PVDF) (Biorad, USA) was soaked in
100% methanol for 10 min and after washing with phosphate buffer saline PBS-
0.01% Tween (Oxoid, Hampshire, UK) the membrane and the filter paper were
soaked with transfer buffer for 15 min.
The gel cassette was opened and the stacking gel was discarded. The transfer
sandwich was assembled in the semi dry unit (Biorad, USA) in the following
order: filter paper/ PVDF membrane/ gel/ filter paper as shown in Figure 2.3. Air
bubbles were removed by rolling a clean test tube over the layers and the unit
was set at 180 mA for 120 min. After transfer, the blot was stained with
Ponceau S to check the successful transfer of protein. The blot was destained
by washing briefly with distilled water five times and finally with PBS-Tween. It
was then blocked with 20 ml of 5% non fat-dry milk in PBS-Tween for 60 min to
block non-specific protein binding sites on the blot. After blocking, the
immobilized proteins were probed overnight at 4oC with specific primary rabbit
anti-ferroportin 1 (1:500, Alphadiagnostics, USA), mouse anti-DMT1 (1:1000,
produced in house), and mouse anti-actin (1:10,000, Abcam, Cambridge, UK)
followed by washing and incubation with donkey anti-rabbit secondary antibody
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horseradish peroxidase conjugate (1:4000). The blot was visualised under
Fujifilm LAS-1000 imager.
Cathode electrode plate
Filter paper, four sheets
Gel
PVDF membrane
Filter paper, four sheets
Anode electrode plate
Figure 2.3 Diagram of transfer sandwich of blotter paper, PVDF membrane, and
gel
The transfer sandwich was assembled to the semi dry unit in this order: filter paper/
PVDF membrane/ gel/ filter paper
2.3.2.3 Polyacrylamide gel
10% polyacrylamide resolving gel was prepared by mixing 6 ml of 30%
acrylamide stock solution (Sigma, Poole, UK), 7.5 ml of distilled water, and 4.5
ml of Tris-HCl buffer with pH 8.8 (Protogel, Leicestershire, UK). 0.01 ml of
TEMED (tetramethylenediamine) (Sigma, Poole, UK), and 0.08 ml of freshly
made 10% (w/v) ammonium persulphate (APS) (Sigma, St. Loius, USA) were
also added as initiators for polymerization reaction. The rate of formation of free
radicals from persulphate is accelerated by TEMED which in turn catalyzes
polymerization. The gel was cast in 1 mm plastic cassettes (Invitrogen,
Carlsbad, USA) at room temperature for 60-90 min and was overlaid with 0.2-
0.3 ml of isopropanol (Sigma, Poole, UK) to avoid any contact with oxygen
present in the air. A 5% stacking gel containing 1.5 ml of 30% acrylamide stock
solution, 1 ml of stacking Tris-HCl buffer, pH 6.8 (National Diagnostics, UK),
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2.47 ml of distilled water, 0.02 ml of APS, and 0.01 ml of TEMED was overlaid
on the resolving gel after discarding the isopropanol. It was then sealed with a
well forming comb which was gently placed to avoid air bubble formation.
2.3.3 Immunoprecipitation
HEK293 Tet-On and Tet-Off cells seeded in 6-well plates were washed with
ice-cold PBS thrice followed by addition of 0.2 ml ice-cold RIPA buffer in each
well. Cells were scraped off the plate and transferred to a 1.5 ml Eppendorf
tube kept on ice. Cells were sonicated four times for 5 seconds and
microcentrifuged for 10 min at 4oC. The supernatant was transferred to a new
tube and protein was quantified from the cell lysate. 200 µg of cell lysate was
mixed with 2 µg of rabbit anti-GFP primary antibody (Abcam, Cambridge, UK)
and incubated with gentle rocking overnight at 4oC. 20 µl of goat anti-rabbit IgG
magnetic beads (New England BioLabs, UK) were added to the cell lysate after
washing with 1 ml ice-cold PBS three times. The tube with the mixture was
incubated at 4oC for 1 hour with gentle rocking. The tube was then placed in a
magnetic separation rack to pull beads to the side of the tube and the
supernatant was discarded. The beads were washed with 1 ml ice-cold PBS for
three times, 40 µl of 2x Laemmli treatment buffer was added to the beads and
incubated at 4oC for 30 min. The tube was placed in a magnetic separation
rack and the supernatant was collected to run on 10% SDS-PAGE and protein
was visualised after transferring to a PVDF membrane (Figure 2.4) as
described in sub-section 2.3.3.2.
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Figure 2.4 GFP protein expression in HEK293 Tet-On hFPN1-GFP cells and Tet-
Off hFPN1-GFP cells
Immunoprecipitation of FPN1 tagged with GFP expression in HEK293 Tet-On
hFPN1-GFP cells and Tet-Off hFPN1-GFP cells. Blot revealing protein expression of
FPN1 tagged with GFP (~90kDa) in positive control (+ve) of both cell lines while no
GFP expression was found in negative control when the expression was turned off.
2.3.4 Protein Quantification
Total protein was quantified from placental tissues and cell samples using the
BCA protein assay kit (Pierce, Rockford, USA). The principle of this method is
based on the biuret reaction when Cu+2 is reduced to Cu+1 by protein in the
presence of bicinchoninic acid (BCA). Firstly, a set of albumin standards was
prepared in vials with a final concentration ranging from 25 to 2000 µg/ml.
Working reagent was prepared by mixing 50 parts of BCA reagent A with BCA
reagent B (v/v). To 200 µl of working reagent, 10 µl of each standard, blank,
and tissue or cell samples were pipetted in duplicate into the microplate well.
The plate was covered and mixed thoroughly on a plate shaker for 30 seconds
followed by incubation for 30 min at 37oC. After incubation the plate was cooled
at room temperature and the absorbance was measured at 570 nm on a plate
reader (Labsystems Multiskan MS, Finland). The average blank reading was
subtracted from each standard. A standard curve was made to determine
protein concentration of each sample. A standard curve is shown in Figure 2.5.
Tet-On Tet-Off
-ve +ve +ve -ve
68
y = 0.0002x + 0.0035
R2 = 0.9971
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Figure 2.5 Standard curve of albumin standard with concentration ranging from
25 to 2000 µg/ml
2.3.5 Hepcidin synthesis and structural analysis
Hepcidin (H-DTHFPICIFCCGCCHRSKCGMCCKT-OH) was synthesized in
house by Ms. Adams in the Dept. of Chemistry, UCL (For details see Jordan et
al. 2009). The peptide mass was confirmed by electrospray mass spectrometry
on a Waters Aquity UPLC-SQD MS system with an applied voltage of 60 V, the
gradient used was 5 to 95% acetonitrile in water over 10 min. The calculated
monoisotopic mass for hepcidin was 2787.1 Da and observed mass was 931.5
Da [MH]3+ which deconvoluted to 2791.5 Da, Figure 2.6 (a). The commercial
hepcidin (Peptide international, USA) the calculated monoisotopic mass was
2789.4 Da; observed mass, 931.42 Da [MH]3+ which deconvoluted to 2791.26
Da, Figure 2.6 (b). To further confirm the similar composition of both peptides,
the samples were run on HPLC (Dionen UltiMate 3000) using a Phenomenex
Sphere Clone (5 µm particle size) and 250 x 4.60 mm column with the gradient
69
of acetonitrile (containing 0.1% TFA) and water (containing 0.1% TFA) over 45
min and a flow rate of 1ml/min, Figure 2.7.
(a)
(b)
Figure 2.6 Electrospray mass spectrometry of commercial and in house hepcidin
The highest peaks in both spectra show the same deconvoluted monoisotonic mass of
commercial (931.42) (a) and in house hepcidin (931.50) (b).
m/z
500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100
Anna_hepcidin_D_foldHPLC 294 (2.670) 1: Scan ES+
1.74e6931.50
501.65
931.20
502.70
859.42
695.46652.41 858.74776.91
925.20
932.17
932.62
1396.44943.87
1396.22
956.62
1145.931040.78
1396.59
1397.49
1398.02
m/z
500 600 700 800 900 1000 1100 1200 1300 1400 1500 1600 1700 1800 1900
%
0
100 1.99e7931.42
931.12
501.73
698.83
931.65
1396.07
1395.47
70
Figure 2.7 HPLC spectra showing commercial and in house hepcidin
The HPLC trace shows hepcidin produced in house in black and the commercial
hepcidin in blue. The difference in height between the two peaks is due to the
concentration of the commercial sample being higher than that of the synthetic
hepcidin.
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2.4 Molecular Biology
2.4.1 RNA extraction and verification
Total RNA was isolated from 50-100 mg of mouse placenta or BeWo cells
grown in 6-well plates using TRIzol reagent (Invitrogen, Paisley, UK), which is a
mono-phasic solution of phenol and guanidine isothiocyanate. The bench top
and Gilson pipettes were wiped thoroughly with RNase Zap wipes (Ambion,
Foster City, USA) to prevent contamination of RNA. The tissue samples were
homogenized in 1 ml of TRIzol reagent with a mortar and pestle (Kontes,
Kimble & Chase, Germany), followed by incubation at 25oC for 5 min to permit
the complete dissociation of nucleoprotein complexes. 0.2 ml of chloroform
(BDH Lab supplies, Poole, UK) was added to each tube which was capped and
shaken vigorously for 15 seconds by hand. The samples were incubated at
25oC for 2 min followed by centrifugation at 10,000 rpm for 15 min at 4oC for
separation. In this step, the mixture was separated into a colourless upper
aqueous phase with RNA and a lower phenol-chloroform phase. The aqueous
phase was transferred to a fresh tube and RNA was precipitated from this
phase by mixing with 0.5 ml isopropyl alcohol (Sigma-Aldrich, St. Louis, USA).
Samples were incubated at 25oC for 10 min and centrifuged at 10,000 rpm for
10 min at 4oC. The supernatant was removed and the gel-like RNA pellet was
washed once with 1.5 ml of 75% (v/v) ethanol (VWR, Leicester, UK) by
vortexing briefly. The samples were centrifuged at 7500 rpm for 5 min at 4oC.
Ethanol was removed from the tube and the pellet was air-dried at room
temperature for 5 min. The pellet was dissolved in 50-75 µl of
diethylpyrocarbonate (DEPC) water (Ambion, Foster City, USA) by pipetting
several times and incubated at 58oC for 10 min. The RNA concentration was
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quantified on a Nano Drop instrument using a Nano Drop software, and was
stored at -80oC until further use.
To check the purity of RNA, the ratio between the reading at 260 nm and 280
nm (A260/A280) was checked. In DEPC water, a ratio ranging from 1.7 to 2.0
indicates RNA free of protein contamination.
The quality and purity of RNA was also assessed by electrophoresis on an
agarose gel. A 1.0% agarose gel was prepared by mixing 2.5 g of agarose
powder (Seaken, Rockland, USA) with 250 ml of 1x Tris-acetate-EDTA (TAE)
buffer (Sigma, St. Louis, USA). The mixture was heated in a microwave oven
until the agarose was completely dissolved in the buffer. 8 µl of ethidium
bromide (Invitrogen, Paisley, UK) was added to the mixture to facilitate
visualisation of RNA after electrophoresis. The solution was cooled to about
60oC and was poured in to a gel casting tray containing a well comb. The gel
was left to solidify at room temperature. The well comb was removed after the
gel had solidified and the tray was placed in the horizontal electrophoresis tank
which was filled with 1x TAE buffer. 1 to 3 µg of RNA samples were mixed with
1 µl of Blue/Orange 6x loading buffer (Promega, Madison, USA). The DNA
ladder (Promega, Madison, USA) and the samples including negative control
were loaded into the wells and it was run for 45-60 min at 150V. After
electrophoresis RNA bands were visualised under a gel imager.
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2.4.2 cDNA synthesis
RNA was reverse transcribed using a Verso cDNA kit (Thermo Fisher Scientific,
Surrey, UK) to produce complementary DNA. DNase I treatment was
performed to remove genomic and contaminating DNA. For DNase I treatment
1 µg of RNA from each sample was mixed with 1 µl of DNase buffer (Ambion,
Foster City, USA), 0.5 µl of DNAse I (Ambion, Foster City, USA), and 9 µl of
DEPC water. This mixture was first incubated at 37oC for 30 min then incubated
at 70oC for 10 min. 1 µl of Anchored oligo-dT primers was added to the tubes to
provide RNA priming methods for cDNA synthesis and incubated at 70oC for 5
min. Meanwhile a master mix was made by mixing 4 µl of 5 x cDNA synthesis
buffer, 2 µl of dNTP mix, and 1 µl of enzyme mix for each sample. 8 µl of
master mix was added to each tube after incubating with oligo-dT primer and
the tubes were first incubated at 47oC for 1 hour and then 75oC for 10 min in
thermal controlled Cycler PCR (PTC-100, MJ Research Inc., USA). cDNA was
stored at -20oC.
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2.4.2.1 Verification of cDNA
To check the quality of complimentary DNA (cDNA) or to check whether there
was any genomic DNA contamination, a check PCR was performed using
GoTag PCR Core System I kit (Promega, Madison, USA). 1 µl of cDNA was
mixed with 2.5 µl of 5% reaction buffer, 1.5 µl of 25 mM MgCl2, 0.25 µl of 5
µg/µl of GoTag DNA polymerase, 0.5 µl of 10 mM PCR nucleotide mix, 17.25 µl
of nuclease free water, and 2 µl of β-actin primer. The sequence of the primers
is shown in Table 2.1.
Table 2.1 β-actin primer sequences used for check PCR
β-actin forward 5’-ACCTTCAACACCCCAGCCATGTACG-3’
β-actin reverse 5’-CTGATCCACATCTGCTGGAAGGTGG-3’
Tm 65oC
Product length 698 bp
A drop of Mineral Oil (Promega, Madison, USA) was added to avoid
evaporation and the mixture was incubated at 95oC (denaturation) for 5 min, 40
cycles of denaturation at 94oC for 30 seconds, annealing at 60oC for 30
seconds, and extension at 72oC for 1 min followed by an incubation at 72oC for
7 min. The PCR product was cooled to 4oC and run on a 1.5% agarose with
ethidium bromide and visualised under a UV transilluminator.
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2.4.2.2 Agarose gel electrophoresis of cDNA
A 1.5% agarose gel was prepared by mixing 3.75 g of agarose powder
(Seaken, Rockland, USA) with 250 ml of 1x Tris-acetate-EDTA (TAE) buffer
with pH 8.3 (Sigma, St. Louis, USA). The mixture was heated in a microwave
oven until the agarose was completely dissolved in the buffer. 8 µl of ethidium
bromide (Invitrogen, Paisley, UK) was added to the mixture to facilitate
visualisation of DNA after electrophoresis. The solution was cooled to about
60oC and was poured into a gel casting tray containing a well comb. The gel
was left to solidify at room temperature. The well comb was removed after the
gel had solidified and the tray was placed in the horizontal electrophoresis tank
which was filled with 1x TAE buffer. 12 µl of PCR product of a cDNA samples
were mixed with 3 µl of Blue/Orange 6x loading buffer (Promega, Madison,
USA). The DNA ladder (Promega, Madison, USA) and the samples including
the negative control were loaded into the wells and it was run for 45-60 min at
150V. After electrophoresis PCR product was visualised under a UV
transilluminator (Figure 2.8).
Figure 2.8 Image of agarose gel showing bands of PCR product from cDNA
copied from RNA isolated from BeWo cells
Lane 1-3 show the bands of cDNA synthesized from untreated BeWo cells while lane
4-6 show the cDNA of BeWo cells treated with 1 µM hepcidin for 2 hours. Lane 7
shows the DNA ladder.
cDNA 698 bp
1 2 3 4 5 6 7
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2.4.3 Real-time PCR
Real-time quantitative gene analysis was performed using a Quantitect SYBR
Green PCR kit (Qiagen, Crawley, UK), and a Lightcycler System II (Roche
Diagnostics, Mannheim, Germany) with Lightcycler version 3.5 software (Roche
Molecular Biochemicals, Mannheim, Germany). 1 µg of cDNA was mixed with
10 µl of SYBR Green dye, 8 µl of nuclease free water, and 0.5 µl of each
forward and backward primer. Primers were designed using Primer Express 3
software. The sequence of the primers and additional information is given in
Table 2.2 and 2.3. All the experiments were performed in duplicate in parallel
with the house keeping gene (β-actin or GAPDH).
2.4.3.1 Cycling parameters of Real-time PCR
The PCR cycling conditions were initiated by a denaturation step at 95oC for 10
min, followed by 40 cycles of denaturation at 95oC for 15 seconds, annealing at
60oC for 20 seconds, and extension at 72oC for 40 seconds. The fluorescence
acquisition was set at 65oC for 15 seconds. Melting curve analysis was
recorded after every RT-PCR run.
The relative expression ratio of the gene of interest to housekeeping gene was
calculated by the Lightcycler Relative Quantification software version 1.0 (Real
Quant) (Roche Diagnostics GmbH, Germany).
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Table 2.2 Mouse primer sequences used for real-time PCR analysis
Primer Accession Number* Forward 5´---------------3´ Tmo Reverse 5´---------------3´ Tmo Product length
β-Actin NM_007393.2 GACGGCCAAGTCATCACTATT 65.0 CCACAGGATTCCATACCCAAGA 66.8 88
DMT1 BC019137.1 GGCTTTCTTATGAGCATTGCCTA 65.1 GGAGCACCCAGAGCAGCTTA 66.7 96
DMT1+IRE AF029758 TGTTTGATTGCATTGGGTCTG 65.7 CGCTCAGCAGGACTTTCGAG 67.5 106
DMT1-IRE AK049856.1 CTGCTGAGCGAAGATACCAG 62.7 GTAAACCATAGAAACACACTGG 57.6 102
FPN 1 BC003438.1 CCAGCATCAGAACAAACACG 64.3 ACTGCAAAGTGCCACATCC 63.8 174
Hepcidin 1 AF503444.1 CCTATCTCCATCAACAGATG 57.0 AACAGATACCACACTGGGAA 59.4 170
TfR1 MMTRRMRNA CAGAAAGTTCCTCAGCTCAACCA 66.6 GTTCAATTCAACGTCATGGGTAAG 65.1 92
TfR2 NM_015799.3 AGCTGGGACGGAGGTGACTT 67.3 TCCAGGCTCACGTACACAACA 66.7 100
ZIP14 BC021530.1 GTAAACCTTGAGCTGCAC 55.8 TGCAGCCGCTTCATGGT 67.1 67
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Table 2.3 Human primer sequences used for real-time PCR analysis
Primer Accession Number* Forward 5´---------------3´ Tmo Reverse 5´---------------3´ Tmo Product length
GAPDH NM_002046 TGGTATCGTGGAAGGACTC 60.1 AGTAGAGGCAGGGATGATG 59.2 93
DMT1 NM_001174130.1 GTCATTGGCTCAGCCATTGC 67.9 ATGCCCTTGAGTACCTGGCT 64.8 188
H-Ferritin NM_002032.2 CGCCGCCTCTCCTTAGTC 65.0 GTTCTTCAAAGCCACATCATCG 65.6 138
L-Ferritin NM_000146.3 CCTCCTACACCTACCTCTG 56.2 GCTGGCTTCTTGATGTCC 56.7 143
FPN 1 NM_014585.5 CGTCATTGCTGCTAGAATCG 63.4 AGACTGAAATCAATACGAGC 55.9 164
Hepcidin NM_021175.2 CTGCAACCCCAGGACAGAG 66.0 GGAATAAATAAGGAAGGGAGGGG 65.2 151
TfR1 NM_003234.2 TATAGAAGGTTTGGGGGCTGTG 60.3 GAGACCCTATGAACTTTTCCCTA 63.2 157
Zp NM_001098672.1 CAAGTGGACAGTGCCTGAGA 64.3 CATTGAGGACGCCCTTTTTA 63.7 110
ZIP14 NM_001135153.1 GTCTGGCCTTTGGCATCCT 66.5 AGGGAACATATCAGCCAGAGAAAT 64.8 62
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2.4.3.2 Melting curve analysis of Real-time PCR
Melting curve analysis was performed after PCR amplification cycles. Melting
temperature of dsDNA was based on its base pair length and G-C content.
Analysis of the melting curve was useful to identify unwanted PCR by-products
such as primer-dimers and nonspecific products. The analysis involved heating
the PCR product at 65oC for 10 seconds followed by a slow increase in
temperature to 95oC with a rate of 0.5oC per second, whilst the fluorescence
was recorded continuously. SYBR green binding and fluorescence emission
was maximal at 65oC because of the presence of dsDNA in the PCR product
and with the increase in temperature DNA starts denaturing. This denaturation
resulted in dissociation of SYBR green and reduced fluorescence. Melt curves
were made by plotting fluorescence against temperature. The presence of
primer-dimers and non-specific products were identified by this method as they
usually melt at lower temperatures than the desired products. The presence of
a single peak in the melting curve confirmed the specificity of the primers used.
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2.5 Tissue and serum iron parameters
2.5.1 Measurement of liver, spleen and placental non-haem iron
Liver and placental tissue samples from mice were placed in open 1.5 ml
eppendorf tubes and oven-dried at 55oC for 72 hours. Dried samples were
weighed and placed in fresh tubes. Samples were incubated at 65oC for 20
hours with 1 ml of acid solution (30% HCl and 10% trichloroacetic acid). A
blank was prepared in the same way excluding the sample. Samples were
cooled at 25oC before preparing the blanks, standards and samples in plastic
cuvettes in triplicate with the amounts as detailed in Table 2.4. The sample
mixtures were incubated at 37oC for 10 min before measuring the absorbance
at 560 nm against a water blank with a spectrophotometer.
Table 2.4 Amounts of working chromogen reagent, iron standard,
blank/sample, and distilled water
Working
Chromogen
reagent (ml)
Iron standard (µl) Blank/Sample
(µl)
Distilled water (µl)
Blank 1 0 25 blank 225
Standard 1 125 25 blank 100
Samples 1 0 25 sample 225
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2.5.2 Serum iron measurements
Serum iron was measured in mouse serum using a kit (Pointe Scientific Inc.) as
instructed by the manufacturers. 40 µl of each standard, serum sample and
water was added into standard, sample, and blank wells of 96 well plates. 200
µl of iron buffer reagent was added to all wells and the absorbance reading
(A1) was taken at 560nm by a plate reader after mixing the reagents in the
wells. The 96-well plate was incubated at 37oC for 10 min after adding 4 µl of
iron colour reagent. The absorbance was measured at 560 nm named A2 and
the serum iron was measured with the following equation:
Serum iron = A2 sample – A1 sample x 500 (µg/dl)
A2 standard- A1 standard
2.5.3 Measurement of serum unsaturated iron binding capacity (UIBC)
40 µl of each standard and sample was added to standard and sample wells.
80 µl of water was added to the blank well and 40 µl of water was added to a
standard well. 40 µl of iron standard was added to the sample wells.
Absorbance reading (A1) was measured at 560 nm after adding and mixing
160 µl of UIBC reagent. Then the plate was incubated at 37oC for 10 min after
the addition of 4 µl of iron colour reagent and the absorbance (A2) was
checked at 560 nm. UIBC, total iron binding capacity (TIBC), and transferrin
saturation (TFS) were measured by using the following equations:
UIBC (µg/dl) = 500 - A2 sample – A1 sample x 500
A2 standard- A1 standard
TIBC = iron levels + UIBC
TFS = 100 x Serum iron (µg/dl) / TIBC (µg/dl)
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2.6 Data analysis
Statistical analysis of the data was performed using the software package
GraphPad Prism™ (GraphPad Software, San Diego, CA USA). All the results
are presented as the mean+SEM using Excel and one-way ANOVA followed by
the student’s unpaired t-test. Means were considered significantly different if p-
values were less than 0.05. Variance within treatment groups were expressed
as standard error of the mean (SEM). Experiments on all the cell lines were
carried out three times with four samples in each set.
2.7 General information of reagents
General reagents were supplied by Sigma, Poole, UK unless otherwise stated.
2.8 Stocks, Solutions, and Buffers
30% acrylamide stock solution
Acrylamide 29.2 g
Bis (N, N’-methylenebisacrylamide) 0.8 g
Per 100 ml of distilled water
1.5 M Tris-HCl buffer, PH 8.8
Tris hydroxymethyl aminomethane (Tris) 8.2 g
Sodium dodecyl sulphate (SDS) 0.4 g
HCl 2 ml
Per 100 ml of water
0.5 M Tris-HCl buffer, pH 6.8
Tris 6.1 g
SDS 0.4 g
HCl 4.2 ml
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Tank Buffer (Tris-Glycine-SDS buffer) pH 8.6
Tris 25 mM
Glycine 192 mM
SDS 0.1%
Transfer Buffer (Tris-Glycine-SDS-methanol buffer)
Tank buffer 80%
Methanol 20%
Hepes buffer, pH 7.4
NaCl 136 mM
KCl 5 mM
CaCl2 1 mM
MgCl2 1 mM
Hepes 18 mM
Acid Solution (30% HCl and 10% trichloroacetic acid)
HCl (36.5%) 41.1 ml
Trichloroacetic acid 5 g
Volume was made up to 50 ml with distilled water
Stock iron standard solution, 20 mM
Carbonyl iron powder 22.3 mg
HCl (36.5%) 1.096 ml
Solution was left to stand overnight at RT and volume was made up to 20ml
with distilled water
Working iron standard solution, 200 µM
Stock iron standard solution 0.5 ml
HCl (36.8%) 0.27 ml
Volume was made up to 50 ml with distilled water
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Chromogen reagent (0.1% bathophenanthroline sulphonate and 1%
thioglycolic acid)
Dissodium-4,7-diphenyl-1,10-phenanthroline sulphonic acid 50 mg
Distilled water 25 ml
Thioglycolic acid (100%) 0.5 ml
Volume was made up to 50 ml with distilled water
Chromogen working solution
Distilled water 20 ml
Saturated sodium acetate 20 ml
Chromogen reagent 4 ml
Iron standard solution
Distilled water 0.423 ml
HCl 0.027 ml
Stock iron solution 0.050 ml
50x Tris-acetate-EDTA (TAE) buffer
Tris base 242g
EDTA pH 8.0 0.5 M (100ml)
Glacial acetic acid 57.1 ml
Volume was made up to 1000 ml with distilled water, diluted 1x for working
solution
RIPA buffer
NaCl 8.6 g
Tris HCl 1.6 g
EDTA.2H2O 0.4 g
NP40 10 ml
20% SDS 5 ml
Volume was made up to 1000 ml with distilled water
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Chapter 3
Hfe-dependent regulation of iron transfer
across the placenta
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3.1 Introduction
Iron requirement during pregnancy in humans increases as the gestation
progresses. The reasons for high iron requirements are mainly due to the
expansion of blood volume in the mother and the transfer of iron to the
growing foetus, which reaches a maximum limit during the third trimester
(Hallberg 1988). Iron deficiency anaemia in pregnant mothers is common
even in developed countries (Bothwell et al. 1979). This can result in
premature birth, developmental problems in the foetus and risk of high blood
pressure in adulthood (Crowe et al. 1995; Gambling et al. 2003 a).
A few studies suggest that more than 30% of women in their child bearing age
in developed countries do not have adequate iron stores (Hallberg 1995;
WHO 2001). WHO reported iron deficiency anaemia in 18% of pregnant
women in industrialised countries (WHO 1993; 2001). Therefore, WHO has
recently recommended iron-folic supplementation or fortification of staple food
in areas where the prevalence of anaemia is more than 20% in women of
child bearing age (WHO 2009). This shows the importance of iron in the diet
of fertile women to start gestation with adequate iron stores in order to avoid
prenatal iron supplementation, which is considered as controversial. Previous
studies have shown the risk of increased oxidative stress and haem
concentration affecting the health of pregnant women and foetal development,
when given iron supplementation (Casanueva & Viteri 2003; Milman 2006).
Many proteins involved in iron influx and efflux across the apical (maternal
side) and basolateral (foetal side) membranes of syncytiotrophoblasts have
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been identified but there are still unanswered questions about the mechanism
of regulation and transport of iron across the placenta. However, it has been
postulated that in the syncytiotrophoblasts, iron is taken up by TfR1 (a protein
important for cellular iron uptake) on the microvillar membrane, followed by
internalization into the endosome. The release of iron into the cytosol
probably occurs through DMT1 (an iron channel protein) after the acidification
of the vesicle, and is transferred across the basolateral membrane via FPN1
(reviewed in Gambling et al. 2003 b).
HFE, a 343 amino acid membrane protein, mutated in hereditary
haemochromatosis, predominantly expressed in liver hepatocytes (Zhang et
al. 2004) is also found in placental syncytiotrophoblasts (Parkilla et al. 1997).
It is believed that HFE competes with Tf to bind TfR1 on the apical side of the
syncytiotrophoblasts (Feder et al. 1998). In a recent study, introduction of
mutations into mice to strengthen the TfR1-HFE interaction showed that this
interaction was responsible for hepcidin deficiency and iron-overload in mice
(Schmidt et al. 2008). On the other hand, mice with mutations that interfere
with the TfR1-HFE interaction or mice with higher HFE levels than normal had
iron deficiency and high hepcidin levels. This provides strong evidence that
HFE induces hepcidin expression that in turn regulates intestinal iron
absorption. However, very little data is available on the role of HFE in
regulating iron transport across the placenta.
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The aim of this research is to identify the mechanism of iron transport across
the placenta regulated by maternal or foetal Hfe and the effect of different
levels of iron in the maternal diet.
3.2 Experimental design
All experimental procedures were approved and conducted in accordance
with the UK Animals (Scientific Procedures) Act, 1986. Hfe knockout (KO)
mice were used, which were mixed 129/Ola-C57BL/6 background strain, with
a 2kb pgk-neor gene flanked by loxP sites replacing a 2.5kb BglII fragment
(Bahram et al, 1999). Hfe KO mice were mated with wild type (WT) mice to
produce progeny of heterozygous (HET). HET females were mated with HET
males to produce progeny of all genotypes.
After weaning, 21 day old mice were fed a high iron diet (150ppm) for a week
and the dams were divided into three groups. The three groups were fed on
iron deficient (12.5ppm), normal/adequate (50ppm) or high iron (150ppm)
diets. Three weeks later, dams of all genotypes were mated with HET males
and were kept on their respective diet throughout pregnancy (Figure 3.1).
The confirmation of pregnancy was detected by a vaginal plug and this day
was denoted day 0.
Term in mice is 18 to 21 days, so we chose day 18 (D18) of gestation to
sacrifice dams. On D18, dams from each group were anaesthetised with
pentobarbitone. The foetuses were delivered by caesarean section and killed
by decapitation. Dam’s blood, liver, spleen, placenta and the foetal liver were
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collected by Dr. Sara Balesaria, UCL Royal Free Campus, UK. After
collection, tissues were snap frozen in liquid nitrogen and stored at -80oC until
used. All animals were reared in a 12 hour light/12 hour dark cycle and given
food and water ad libitum.
Figure 3.1 Schematic diagram showing the experimental design 1
WT dams were mated with Hfe KO males which produced progeny of HET mice.
HET females were then mated with HET males to produce progeny of all genotypes.
They were fed 150ppm dietary iron for one week after weaning. The dams were
divided into 3 groups on the basis of iron content in diets. They were fed their
respective diets for 3 weeks.
WT
HET
Hfe KO
Progeny F1
Mating
WT Hfe KO
After weaning, mice of each genotype, were fed on a high iron diet (150ppm) for a week
Female mice
WT HET Hfe KO
Iron deficient diet (12.5ppm)
WT HET Hfe KO
Iron sufficient diet (50ppm)
WT HET Hfe KO
High iron diet (150ppm)
Mice were given their respective diet for 3 weeks before mating with HET males and the
diets were maintained throughout pregnancy until day 18 of gestation (D18). At D18
pregnant dams were sacrificed and their blood and tissues were collected including tissues
from foetus
HET
HET
Progeny F2
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3.2.1 Experimental design to determine the effect of maternal genotype
and dietary iron levels on maternal and foetal iron homeostasis
Female mice were divided into three groups and fed on diets with different
iron content for three weeks. To study the effect of maternal Hfe on iron
transport across the placenta, WT and Hfe KO dams were mated with HET
males. From the progeny HET pups were selected. At D18, dams were
sacrificed and the placenta and liver of HET pups were collected in order to
keep the genotype of the foetus or pups same, Figure 3.2 (a). Blood, liver and
spleen of pregnant dams were also collected.
Figure 3.2 (a) Schematic diagram showing the experimental design 2 (a)
WT and Hfe KO dams were mated with HET males and HET pups were selected
from the progeny. On D18, dams were sacrificed and their blood and tissues were
collected. Placental and hepatic tissues of HET pups were also collected.
WT dam Hfe KO dam
Mating
Progeny
HET male HET male
WT pups HET pups Hfe KO pups HET pups
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3.2.2 Experimental design to determine the effect of foetal genotype and
dietary iron levels on maternal and foetal iron homeostasis
To determine the effect of foetal Hfe, HET dams were mated with HET males.
From the progeny, WT and Hfe KO pups were selected and their placental
and hepatic tissues were collected after the pregnant dams were sacrificed on
D18 of gestation, Figure 3.2 (b).
Figure 3.2 (b) Schematic diagram showing the experimental design 2 (b)
HET dams were mated with HET males to produce progeny of all genotypes. On D18
of gestation, dams were sacrificed and their blood and tissues were collected.
Placental and hepatic tissues of WT and Hfe KO pups were also collected.
WT pups HET pups Hfe KO pups
Mating
Progeny
HET maleHET dam
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3.3 Results
3.3.1 Effect of maternal genotype and different dietary iron levels on
maternal and foetal iron homeostasis
3.3.1.1 Serum iron levels and transferrin saturation of WT and Hfe KO
pregnant dams
At term (D18), serum iron levels in WT pregnant dams fed on an iron
deficient diet (12.5ppm) was the lowest. In the second group of WT
dams fed on normal dietary iron, there was a trend towards increased
iron levels in serum but the difference did not reach significance
between WT pregnant dams fed on low and normal iron diets. However,
in WT dams, the level of serum iron increased significantly from 39.87
µg/dL to 104.42 µg/dL (p=0.01) when fed 12.5ppm and 150ppm iron in
diets, respectively. It appeared that serum iron levels in Hfe KO dams,
fed 12.5ppm and 150ppm iron diets, differed largely ranging from 38.79
µg/dL to 181.53 µg/dL (p=0.0002), respectively. Overall, Hfe KO dams
had higher iron levels in their serum as compared with WT except when
fed an iron deficient diet, Figure 3.3 (a).
Transferrin saturation (TFS) in the serum of WT pregnant dams seemed to
increase with the increase in dietary iron intake but the difference was not
significant between WT dams fed on 12.5 and 50ppm dietary iron. The
difference was found to be significant (p=0.01) between WT pregnant dams
fed on 12.5ppm and 150ppm iron content in diets. Surprisingly, it did not alter
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in Hfe KO dams ingesting varying levels of iron in diet and was not correlated
with the serum iron levels. Moreover, TFS was also affected by Hfe status of
the dams as were serum iron levels with an increased concentration found in
Hfe KO as compared with WT dams, Figure 3.3 (b). Together these findings
suggest that HFE status and increased dietary iron can result in increased
circulation of iron in the body during pregnancy.
Figure 3.3 (a) Serum iron levels in WT and Hfe KO pregnant dams fed different
levels of dietary iron.
Serum was separated from the blood taken from WT and Hfe KO pregnant dams on
D18 of gestation. Iron level in serum seems to be increased with the increase in
dietary iron content irrespective of maternal genotype. Bars denote mean + SEM of
four samples from each group. p value in magenta colour shows the significance
difference between the Hfe KO dams while p value in blue colour represents the
difference between WT dams fed diets containing different iron content.
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Figure 3.3 (b) Transferrin saturation in the serum of WT and Hfe KO pregnant
dams
Serum was separated from the blood taken from WT and Hfe KO pregnant dams on
D18 of gestation .Pregnant dams lacking Hfe have significantly higher TFS in their
serum as compared with WT dams but this does not seem to be affected by the
dietary iron content. Bars show mean + SEM and statistically significant values
between each iron diet and each genotype are indicated by different letters above the
bars (p<0.05; n = 4). However, letters ab indicate that there is no significant
difference between a and ab; ab and b.
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3.3.1.2 Liver and spleen iron levels of WT and Hfe KO pregnant dams
Iron in liver was measured in order to determine the effect of dietary iron
content and the role of maternal genotype. On a low iron diet, dams from both
genotypes stored almost the same amount of iron in their livers. However, as
the iron content increased in the diet, Hfe KO dams started storing more iron
in their liver as compared with WT dams, Figure 3.4 (a). The iron content
increased almost 2 fold in Hfe KO pregnant dams fed a high iron diet and
correlated with high serum iron and TFS levels (unpublished data taken from
Dr. Balesaria)
Spleen iron levels seemed not to be affected by the genotype of the dams.
However, spleen from the dams of both genotypes fed a diet with 150ppm
iron had higher iron content, Figure 3.4 (b).
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Figure 3.4 (a) Liver iron levels of WT and Hfe KO pregnant dams fed on diet
containing 12.5ppm, 50ppm or 150ppm iron
WT dams fed a diet with 50ppm or 150ppm iron content have significantly lower
hepatic iron storage as compared with Hfe KO dams. Statistically significant values
(p<0.05) between dams of each genotype fed different dietary iron content are
indicated by different letters (a, b or c) above the bars representing mean+SEM.
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Figure 3.4 (b) Spleen iron levels of WT and Hfe KO pregnant dams fed on diet
containing 12.5ppm, 50ppm or 150ppm iron
Genotype does not seem to affect the spleen iron storage. However, dams fed on a
diet with 150ppm iron content have higher iron storage in their spleen than dams fed
12.5 and 50ppm dietary iron. Bar represents mean + SEM of 10 samples and
different letters (a,b,or c) above the bars shows significant difference between dams
of both genotypes fed different iron content in diets.
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3.3.1.3 Placental iron levels of HET pups from WT and Hfe KO dams
To further investigate whether the placenta is storing more iron, placental iron
levels were measured when the Hfe KO dams have higher liver and serum
iron levels. When fed a normal iron diet (50 ppm), the placenta of HET pups
from Hfe KO mice have higher iron levels as compared with the placenta from
WT dams. In contrast, HET foetuses from dams of both genotypes fed
150ppm dietary iron content have the same amount of iron in their placenta as
shown in Figure 3.5.
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Figure 3.5 Placental iron levels in HET pups from WT and Hfe KO dams
Placenta was collected at D18 of gestation and iron was quantified. When fed a
normal iron diet, the placenta of HET pups from Hfe KO mice have more iron as
compared to WT dams. Placenta has almost same amount of iron regardless of
genotypes of the dams when fed a high iron diet. Bars represent mean + SEM of 8
samples from each category and * shows significant difference at p-value 0.01.
*
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3.3.1.4 Placental gene expression of HET pups from WT and Hfe KO
dams fed a diet containing 12.5ppm, 50ppm or 150ppm iron
Transcript levels of TfR1, an iron uptake membrane protein, DMT1+IRE, an
intracellular metal transporter, and FPN1, an iron efflux protein, were
measured by RT-PCR. DMT1+IRE expression was increased about two-fold
in HET pups from Hfe KO dams compared to HET pups from WT dams fed an
iron deficient diet (P=0.04). However, neither FPN1 nor TfR1 mRNA
expression altered significantly in HET pups from the two different genotypes
of dams fed iron deficient diet, Figure 3.6 (a). When the dams were fed a
normal iron diet, the mRNA expression of the above mentioned iron
transporter genes was up-regulated in the placenta of HET pups from Hfe KO
dams compared to HET pups from WT dams indicating that maternal Hfe
regulates important iron transporter genes. There was a significant increase of
almost two-fold in mRNA expression of all the genes tested, Figure 3.6 (b).
HET pups from Hfe KO dams fed a high iron diet have significantly higher
placental FPN1 mRNA expression (p=0.01) than HET pups from WT dams
and no significant difference was found in TfR1 and DMT1+IRE expression
between the pups from WT and Hfe KO mothers (P≥0.05), Figure 3.6 (c).
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Figure 3.6 Relative placental gene expression in HET pups from Hfe KO and
WT dams fed diets with different iron contents
mRNA expression of FPN1, TfR1 and DMT1+IRE in placenta was analysed by RT-
PCR (a) Placental expression of DMT1+IRE was significantly decreased in HET pups
from WT dams fed an iron deficient diet, whereas no change was observed in FPN1
and TfR1 expression levels. (b) Expression of FPN1, TfR1 and DMT1+IRE was
significantly higher in the placenta of HET pups from Hfe KO dams as compared to
pups from WT dams fed an iron sufficient diet. (c) When the dams were fed a high
iron diet, placental FPN1 expression was higher in HET pups from Hfe KO dams.
Bars indicate mean+SEM. * denotes significant difference between the groups at
p<0.05 while *** denotes p<0.0001.
* * *
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3.3.1.5 Comparison of placental gene expression in HET pups from WT
and Hfe KO dams fed different amounts of iron in the diet
The placental FPN1 mRNA expression was compared in the HET pups from
dams of different genotypes fed 12.5ppm, 50ppm and 150ppm dietary iron.
Overall there was higher placental FPN1 expression in HET pups from Hfe
KO dams as compared with HET pups from WT dams fed normal or high iron
diets. When fed an iron deficient diet, the difference in the expression of FPN1
mRNA did not reach significance, Figure 3.7.
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Figure 3.7 Comparison of placental FPN1 mRNA expression in HET pups from
WT and Hfe KO dams
Line graph represents Mean+SEM and shows higher placental FPN1 mRNA
expression in HET pups from Hfe KO dams as compared with HET pups from WT
dams fed normal or high iron diets. * denotes significant difference between the
groups at p<0.05.
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TfR1 mRNA expression was down-regulated in the placenta of HET pups
from WT dams fed a normal iron diet as compared with pups from WT dams
on iron deficient and supplemented diets. There was not any significant
difference in the TfR1 mRNA expression in HET pups from KO dams raised
on varying iron diets, Figure 3.8.
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Figure 3.8 Comparison of TfR1 mRNA expression in HET pups from WT and
Hfe KO dams on varying iron diets
Line graph represents Mean+SEM and shows lower TfR1 mRNA expression in HET
pups from WT dams fed 50ppm dietary content. * denotes significant difference
between the groups at p<0.05.
*
102
When fed iron deficient and normal diet, placental DMT1+IRE expression was
significantly higher in HET pups from Hfe KO dams as compared with the
placenta from WT dams. On iron sufficient diet (150ppm), due to higher
variation in the results, the difference in the DMT1+IRE expression between
the placenta of HET pups from WT and Hfe KO did not reach significance.
However, placental DMT1+IRE mRNA expression was increased in HET pups
from both genotypes of dams (WT and Hfe KO) fed on 150ppm iron diet as
compared with pups from dams fed 12.5 and 50ppm iron content in diet,
Figure 3.9.
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Figure 3.9 Comparison of DMT1+IRE mRNA expression in HET pups from WT
and KO dams on varying iron diets
Line graph represents Mean+SEM and shows increased DMT1+IRE mRNA
expression in HET pups from WT dams fed 12.5, 50 and 150ppm iron content in diet.
* denotes significant difference between the groups at p<0.05.
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3.3.1.6 Placental FPN1 protein expression in HET pups from WT and Hfe
KO dams fed different amounts of iron in the diet
FPN1 protein was expressed in all samples. The amount of FPN1 protein was
higher in the placenta of HET pups from Hfe KO dams as compared with the
HET pups from WT dams fed the three different iron diets, Fig 3.10 (a) and
(b).
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Figure 3.10 Placental FPN1 protein expression of HET pups from WT and HFE
KO dams fed different dietary iron
(a) Western blot revealing protein expression of FPN1 (~60kDA) and β-actin (40-
45kDa) in placental tissues of HET pups from WT and HFE KO dams. Lanes 1and 2
correspond to FPN1 protein expression in placenta of HET pups from WT dams and
lanes 3 and 4 correspond to HET pups from HFE KO dams fed different dietary iron
probed with antibody against FPN1. (b) Histogram of relative FPN1 protein
expression showing lower protein expression in HET pups from WT dams fed
different dietary iron. Histogram represent mean of 3 samples from each group.
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13.3.1.7 Liver iron levels of HET pups from WT and Hfe KO dams
To analyse the effect of maternal genotype on foetal liver iron stores, liver iron
levels of HET pups from WT and Hfe KO dams were determined. Foetal liver
iron levels indicated that maternal genotype had an effect on iron
accumulation in foetal liver because HET pups from HFE KO dams had
significantly higher liver iron content than HET pups from WT dams fed either
50 or 150ppm iron diet. No significant difference was found in the foetal liver
iron level when the dams were fed an iron deficient diet (12.5ppm iron diet),
Figure 3.11. This might be because dams of both genotypes struggled to
transfer iron to their foetuses. Foetal liver iron level in HET pups from dams of
both genotypes, fed an iron deficient diet, had significantly lower iron storage
in liver than pups from dams fed an iron adequate or replete diet.
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3.3.2.1 Serum iron concentration and transferrin saturation of pregnant
HET dams fed different dietary iron
At term, HET dams fed a high iron diet had more serum iron and higher
transferrin saturation in their circulation than HET dams fed deficient or
normal iron diets, Figure 3.12 (a) and (b).
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3.3.2.2 Liver and spleen iron levels of pregnant HET dams
High iron concentration in the circulation of pregnant HET dams, fed a high
iron diet resulted in high iron storage in the maternal liver and spleen as
compared with HET dams fed a deficient or normal iron diets, Figure 3.13 (a)
and (b).
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Figure 3.13 Liver and spleen iron levels in pregnant HET dams fed varying
levels of dietary iron
(a) Livers from pregnant HET dams were collected on D18 of gestation and iron
level was measured by spectrophotometric analysis. Dams on a high iron diet had
significantly higher liver iron storage. (b) Similarly, spleen iron levels were higher in
dams fed a diet with 150ppm iron content. Bars represents mean+SEM and * show
the significance difference between liver and spleen iron levels of HET dams on
replete iron diet as compared with dams on iron deficient or sufficient diets.
* *
3.3.2.3 Placental iron levels of WT and Hfe KO pups from HET dams
Placental iron levels did not appear to be affected by the dietary iron and
genotype of the pups from HET dams, Figure 3.14.
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3.3.2.4 Placental gene expression in WT and Hfe KO pups from HET
dams
Placental FPN1, TfR1 and DMT1+IRE mRNA expression did not appear to
alter significantly in WT and Hfe KO pups from HET dams that were fed an
iron deficient or a normal diet, Figure 3.15 (a) and (b). There was a
significantly higher expression of DMT1+IRE mRNA in Hfe KO pups from HET
dams raised on a 150ppm iron diet (p=0.001) as compared with the WT pups
from HET dams, Figure 3.15 (c).
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3.3.2.5 Placental FPN1 protein expression in WT and Hfe KO pups from
HET dams fed different dietary iron
FPN1 protein expression seemed to be higher in the placenta of WT pups
from HET dams fed low or normal dietary iron. However, when the dams were
fed high iron diet FPN1 protein was increased in the Hfe KO pups of Het
dams. The western blot image showing FPN1 and β-actin bands is shown in
Figure 3.16 (a) and the histogram is shown in Figure 3.16 (b).
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Figure 3.16 Placental FPN1 protein expression of WT and Hfe KO pups from
HET dams
(a) Western blot revealing protein expression of FPN1 (~60kDA) and β-actin (40-
45kDa) in placental tissues of WT and Hfe KO pups from HET dams. Lanes 1and 2
correspond to FPN1 protein expression in placenta of WT pups from HET dams and
lanes 3 and 4 correspond to Hfe KO pups from HET dams fed different dietary iron.
(b) Histogram of relative FPN1 protein expression and Bars represent mean of 3
samples from each group.
FPN1 (~60 kDa)
WT pups
from HET
dams
KO pups
from HET
dams
WT pups
from HET
dams
KO pups
from HET
dams
WT pups
from HET
dams
KO pups
from HET
dams
β-actin (40-45 kDa)
12.5ppm
dietary iron
50ppm
dietary
150ppm
dietary iron(b)
(a)
111
3.3.2.6 Liver iron levels of WT and Hfe KO pups from HET dams
To study the effect of foetal Hfe, HET dams were mated with HET males and
foetuses with Hfe KO and WT genotypes were selected and their liver iron
levels were quantified. Results showed that liver iron accumulation was
highest in Hfe KO pups from HET dams fed a diet with a high iron content
(150 ppm), Figure 3.17.
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Figure 3.17 Liver iron levels of KO and WT pups from HET dams
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3.4 Discussion
During the third trimester of pregnancy, iron is transported from mother to
foetus against a concentration gradient. It is clear from previous studies that
iron transport across the placenta is regulated to avoid iron deficiency or
overload which can affect the development and function of red blood cells,
brain, heart and liver of the foetus (Grantham-McGregor and Ani 2001; Choi
et al. 2000). The mechanism by which Hfe, a negative iron regulator and
modulator of hepcidin production, regulates iron homeostasis in mothers and
foetuses is not clearly understood. In a previous study, Prof. Srai and
colleagues were able to infer by correlation data that foetal liver starts
regulating placental iron uptake when the mothers are given iron deficient and
supplemented diets (Gambling et al. 2001, 2009). Based on these studies
they proposed that foetal liver iron levels, by regulating hepcidin, were
involved in regulating iron transfer across placenta. In the current study, the
mating strategy between WT, HET and Hfe KO mice fed different dietary iron
levels has allowed us to confirm the involvement of foetal liver in iron supply
to the foetus. Our results have also shown that maternal Hfe status and
dietary iron levels play an active role in placental iron transport and
maintaining foetal iron homeostasis.
Previously it had been shown that iron absorption increases in the maternal
gut during pregnancy (O’ Brien et al. 2003; Gambling et al. 2009) with an up-
regulation of DMT1, Dcytb and FPN1 expression in the duodenum of pregnant
WT dams (S. Balesaria, unpublished data). Here, we have found that during
pregnancy maternal serum iron levels, transferrin saturation and body iron
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stores depend on adequate dietary iron intake. WT pregnant dams’ serum
iron levels, transferrin saturation and liver iron stores increased significantly
when fed a high iron diet as compared with dams fed an iron deficient diet. A
number of studies in pregnant women have shown the beneficial effects of
iron supplements including increased iron in the maternal circulation and
reduced prevalence of anaemia (Bothwell et al. 1979; Sloan et al. 1992; Yip
1996; Cogswell et al. 2003). Previous studies have shown Hfe KO non-
pregnant mice accumulating more iron in their liver and increased serum iron
levels (Vujic Spasic et al. 2007). We have confirmed this in Hfe KO pregnant
dams with high serum iron and increased liver iron storage compared with WT
pregnant dams and these two parameters increased with the increase in
dietary iron content. These results are in agreement with previous findings
where low hepatic hepcidin expression during pregnancy (Rehu et al. 2010)
and mutation in Hfe increased duodenal iron absorption which leads to high
maternal serum iron levels (Vujic Spasic et al. 2007). This was further
confirmed in a parallel study by Dr. S. Balesaria (unpublished data), who has
found up-regulation in DMT1, Dcytb and FPN1 expression in the duodenum of
pregnant Hfe KO pregnant dams as compared with non-pregnant dams.
When pregnant dams are fed a low iron diet, iron transport to the foetus
seems to be provided by the maternal body iron stores (liver) resulting in low
maternal hepatic iron levels in both WT and Hfe KO dams.
Iron transport across the placenta is mainly a function of three major
transporter proteins: TfR1 (iron uptake membrane protein), DMT1
(intracellular metal transporter) and FPN1 (iron efflux protein) (Bergamaschi et
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al. 1990; Georgieff 2000; Petry et al. 1994; Verrijt et al. 1999). In order to
protect the foetus from iron deficiency or overload, these proteins are
regulated in the placenta (Georgieff et al. 2000; Donovan et al. 2000,
Gambling et al 2003). To further understand the role of maternal Hfe status
and dietary iron on the expression of these transporters in the placenta, their
mRNA levels were determined. Our results show that TfR1, DMT1 and FPN1
gene expression was higher in HET foetuses from Hfe KO dams fed a normal
dietary iron, with higher placental iron levels, in comparison with those derived
from WT dams. When fed a high iron diet, the expression of placental FPN1
was up-regulated in the Hfe KO dams but placental iron levels remained the
same. This correlates very well with the FPN1 protein expression in the
placenta of foetuses from Hfe KO dams. These data suggest that increased
iron transport across the placenta may be due to increased FPN1 expression
under iron-replete conditions; this was in contrast with dams fed a low iron
diet as also shown in a previous study (O’ Brien et al. 2003). HET foetuses
from Hfe KO dams fed normal and high iron diets had high hepatic iron stores
and higher body weights than those derived from WT dams fed all three
different iron diets (S. Balesaria unpublished data). A study in humans has
demonstrated that babies born from mothers with mutant forms of HFE had
higher body weights at the time of birth (Dorak et al. 2009). In conclusion,
maternal genotype and dietary iron intake play an important role in regulating
placental iron transport and foetal iron accumulation.
To determine the effect of foetal Hfe status in regulating placental iron
transport, iron transporter expression in placenta of WT and Hfe KO foetuses
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derived from HET dams were determined in addition to the measurement of
maternal iron levels and foetal iron stores. Previous studies have shown a
clear contribution of foetal liver hepcidin in regulation of iron transport across
the placenta in WT animals (Gambling et al. 2009). Our data suggested that
Hfe KO pups from HET dams with high iron stores when fed a high iron diet
were unable to control normal regulation of iron uptake which resulted in
increased placental FPN1 expression, more iron transport and high foetal liver
iron levels as compared with WT pups. Hfe KO pups born from HET dams on
a high iron diet also had more body iron (Unpublished data by Dr. S.
Balesaria). This increased iron uptake in Hfe KO pups as compared to WT
pups may be due to the production of hepatic hepcidin in the latter. Our data
suggests that up-regulated placental FPN1 expression by the foetal liver may
have controlled foetal iron uptake. Foetal genotype seemed to affect liver iron
accumulation and FPN1 gene expression only with high iron intake by the
mother.
In conclusion, iron metabolism and production of normal and healthy offspring
during pregnancy is dependent on the iron status and genotype of the mother.
Deletion of Hfe in both dams and pups caused increased iron levels in the
maternal circulation, and storage in the liver; however this effect was clearly
diet-dependent. When mothers are fed a low or normal iron diets, foetal liver
was able to control iron transport across the placenta or its availability to the
foetus.
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Chapter 4
Iron transport across placenta: role of
hepcidin
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4.1 Introduction
The coordinated interaction between hepcidin and the iron exporter (FPN1)
regulates duodenal iron absorption, its storage in the liver and circulation in
the body. Hepcidin is an amphipathic 25 amino acid peptide belonging to the
defensin family of antimicrobial peptides. The role of hepcidin as an iron
regulatory peptide was identified after the deletion of the HAMP1 gene,
responsible for encoding hepcidin. This targeted deletion of the HAMP1 gene
resulted in high iron accumulation in the parenchymal tissues of mice
(Nicholas et al. 2001). Whereas, over-expression of hepcidin resulted in
severe iron deficiency anaemia in mice (Nicholas et al. 2002). These findings
led to the supposition that hepcidin functions as a negative regulator of iron
metabolism.
Previous studies have demonstrated the mode of action of hepcidin by
binding to FPN1 followed by its internalisation and finally degradation
(Nemeth et al. 2004). Hepcidin seems to have a cell-specific response and
previous studies have shown the reduction of FPN1 expression in
macrophages (THP1 cells), erythroblast cell lines and primary erythroblasts
(K569) (Chung et al. 2009; Zhang et al. 2011). However, FPN1 expression
was not altered in duodenal enterocytes (Caco-2 cells) after hepcidin
treatment (Chung et al. 2009). How hepcidin regulates placental iron transport
is not clearly known.
Hfe KO mice absorb and accumulate more iron in their body and can take up
more NTBI than WT mice (Chua et al. 2004; Zhou et al. 1998). A number of
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studies have shown that mutations in the Hfe gene result in an inappropriately
low level of hepcidin expression (Ahmad et al. 2002, Schmidt et al. 2008;
Vujic et al. 2008). The decrease of circulating hepcidin leads to an increased
FPN1-mediated iron efflux from reticuloendothelial cells and duodenal
enterocytes resulting in increased circulating iron and eventually the
saturation of transferrin. Moreover, when Hfe KO mice were crossed with
mice over-expressing hepcidin, their overload status was normalized
(Nicholas et al., 2003). Also, HFE participates in the regulation of intestinal
iron absorption by modulating hepcidin expression (Mura et al., 2004). The
results presented in Chapter 3 have demonstrated that the absence of Hfe in
pregnant dams has increased iron transport across placenta and resulted in
high iron accumulation in the foetal liver. However, there are difficulties in
distinguishing the primary effects of HFE on cellular iron status and its
secondary effects resulting from changes in hepcidin expression. HFE is also
expressed in coated pits on the apical side of syncytiotrophoblasts where it is
believed that it forms a complex with the TfR1 and β-2-microglobulin (Parkkila
et al. 1997). In contrast, Bastin et al. (2006) found HFE on some parts of the
basal syncytiotrophoblasts in large amounts where FPN1 are strongly
expressed. Furthermore, there is very little data on the role of HFE and
hepcidin in the regulation of iron transport across placenta.
The aim of this study is to investigate the regulation of iron transport across
the placenta by studying the coordinated interaction between hepcidin and
FPN1.
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4.2 Experimental design
4.2.1 In vivo studies
All experimental procedures were approved and conducted in accordance
with the UK Animals (Scientific Procedures) Act, 1986. Hfe knockout (KO)
mice were used, which were mixed 129/Ola-C57BL/6 background strain, with
a 2kb pgk-neor gene flanked by loxP sites replacing a 2.5kb BglII fragment
(Bahram et al, 1999). 129/Ola-C57BL/6 mixed background mice strains were
used as WT.
After weaning, mice were fed 150ppm iron diet (150mg Fe/kg diet) for two
weeks followed by mating with males of the corresponding genotype (WT or
Hfe KO). Pregnancy was confirmed by detection of a vaginal plug and the day
this was observed was denoted as day 0. From day 14 of gestation, females
were injected every 24 hours with either 0.15M NaCl or 10µg hepcidin
dissolved in 0.15M NaCl via the intraperitoneal route, Figure 4.1.
On day 18 of gestation, dams from each group were anaesthetised with
pentobarbitone. The foetuses were delivered by caesarean section and killed
by decapitation. Maternal blood and placenta were collected and rapidly
frozen in liquid nitrogen before being stored at -80oC for RNA extraction,
protein purification and tissue non-haem iron measurements.
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Figure 4.1 Experimental design of in vivo studies
WT and Hfe KO pregnant dams were injected with either saline or hepcidin from D14
of gestation and every 24 hours till D18 of gestation. On D18 of gestation, dams were
sacrificed and their blood and placental tissues were collected.
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4.2.2 In vitro studies
BeWo cells were seeded on inserts and treated with hepcidin on either the
apical or the basolateral side when the confluency reached 100%. The
confluent layer of BeWo was observed by measuring the transepithelial
electrical resistance by a TEER voltohmmeter, Figure 4.2. Total RNA or
protein was extracted from BeWo cells after a time course treatment with 1µM
hepcidin.
Figure 4.2 Experimental design of in vitro studies
BeWo cells were polarised by seeding them on inserts and the confluent monolayer
was measured by a TEER voltohmmeter followed by hepcidin treatment on either the
apical or basolateral side.
Insert
Cell culture medium
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Apical side of BeWo cells
Basolateral side of BeWo
cells
Apical treatment
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122
*
4.3 Results
4.3.1 In vivo studies of hepcidin-dependent placental iron transport
4.3.1.1 Effect of hepcidin injection on serum iron levels and transferrin
saturation of WT pregnant dams
Hepcidin was injected in pregnant dams in order to understand its role in
regulating iron transport during the last trimester of pregnancy. Serum iron
levels and transferrin saturation were measured after collection of blood at
D18 of gestation. For control experiments, the dams were injected with the
same amount of saline. Treatment with hepcidin caused a significant
decrease in serum iron levels (p = 0.01). Transferrin saturation was also
reduced after the injection of hepcidin but it did not reach statistical
significance (p < 0.05), Figure 4.3 (a) and (b).
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Figure 4.3 Serum iron levels and transferrin saturation after hepcidin injection
Blood was collected from the pregnant dams at D18 of gestation and serum was
separated from it. (a) Serum iron levels were lowered significantly after injection of
hepcidin. (b) Transferrin saturation is also decreased in hepcidin injected dams but
the difference was not significant. Bar graphs represent Mean + SEM of 6 samples
and * denotes significance at p < 0.05.
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4.3.1.2 Effect of hepcidin injection on placental FPN1 protein and iron
transporter gene expression in WT dams
To further investigate the regulation of iron across the placenta by hepcidin,
FPN1 protein expression was measured by western blot analysis. Placental
tissues were collected 24 hours after the last dose of hepcidin injection.
Increased FPN1 protein expression was observed in hepcidin-treated mice
when compared with controlled WT pregnant mice injected with saline, Figure
4.4 (a) and (b). The expression of DMT1+IRE and ZIP14 was up-regulated in
the placenta of WT pregnant mice injected with hepcidin, while mRNA
expression levels of TfR1, TfR2, DMT1-IRE and FPN1 remained unchanged,
Figure 4.5.
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Figure 4.4 Effect of hepcidin injection on placental FPN1 expression
(a) Western blot analysis of placental tissue lysates from saline and hepcidin injected
pregnant WT dams using an antibody to FPN1; Anti-β-actin was used as a loading
control. (b) Histograms show the mean + SEM of relative band intensity with an
increase in placental FPN1 expression after hepcidin treatment.
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Figure 4.5 Relative placental gene expression after hepcidin treatment of WT
pregnant dams
Quantitative RT-PCR analysis of placental gene expression showed a significant
increase in mRNA levels of DMT1+IRE and ZIP14 in the placenta of WT pregnant
dams injected with hepcidin as compared to control with p<0.05 represented by *,
while the expression of TfR1, TfR2, DMT1-IRE and FPN1 remained unchanged. Bar
graph represents mean + SEM of 6 samples.
*
*
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4.3.1.3 Effect of hepcidin injection on serum iron and transferrin
saturation levels of Hfe KO pregnant dams
To further understand the possible link between HFE and hepcidin in
regulating iron transport across the placenta, Hfe KO pregnant dams were
treated with hepcidin. Serum iron levels and transferrin saturation remained
unchanged in the Hfe KO pregnant dams after the treatment with hepcidin
compared with the dams injected with an equivalent volume of saline, Figure
4.6 (a) and (b).
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Figure 4.6 Effect of hepcidin treatment on serum iron levels and transferrin
saturation of Hfe KO dams
(a) Serum iron levels in Hfe KO pregnant dams did not alter after hepcidin injected.
(b) Transferrin saturation was also the same in saline and hepcidin injected Hfe KO
dam. Data are mean + SEM of 6 samples.
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4.3.1.4 Effect of hepcidin injection on placental FPN1 protein and iron
transporter gene expression of Hfe KO mice
FPN1 protein expression increased in placental tissue collected from
hepcidin-treated Hfe KO pregnant dams as compared with saline injected
dams but the change did not reach significance (p > 0.05). Western blot
images and histograms of mRNA expression are shown in Figure 4.7 (a) and
(b). Hepcidin treatment significantly increased the mRNA expression of TfR1,
DMT1+IRE and ZIP14. On the other hand the treatment had no effect on
TfR2, DMT1-IRE and FPN1 gene expression, Figure 4.8.
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Figure 4.7 Effect of hepcidin injected on placental FPN1 protein expression in
Hfe KO dams
Western blot analysis revealed an increase trend in the placental FPN1 protein
expression in hepcidin injected Hfe KO pregnant dams but the change was not
statistically significance. Bars show the mean of relative band intensity from both
treatments of 6 samples.
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Figure 4.8 Effect of hepcidin treatment on placental iron transporter gene
expression in Hfe KO pregnant dams.
TfR1, TfR2, DMT1+IRE, DMT1-IRE, ZIP14 and FPN1 mRNA expression were
analysed by RT-PCR. Hepcidin treatment increased the mRNA expression of TfR1,
DMt1+IRE and ZIP14 with no change in mRNA expression of FPN1. Bars denotes
mean + SEM of 6 samples per group. * represents p < 0.05 and ** stands for p <
0.001 in hepcidin injected KO mice compared to saline injected controls.
* ***
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4.3.2 In vitro studies of hepcidin-dependent placental iron transport
BeWo cells were used to study the molecular mechanism of iron transport
across syncytiotrophoblasts regulated by hepcidin.
4.3.2.1 Transepithelial electrical resistance of BeWo cells
BeWo cells were grown on the anopore inserts and the transepithelial
electrical resistance (TEER) was measured daily from the 3rd day of seeding
until confluence was obtained on day 8 or 9 post seeding. The TEER readings
increased as the number of cells increased.
Days post seeding 3 4 5 6 7 8 9
TEER (Ωcm2) 107 150 182 204.5 244.9 309.3 321.6
SD + 5.6 5.8 8.4 6.7 6.9 5.01 9.17
Table 4.1 Transepithelial electrical resistance of BeWo cells grown on inserts
The resistance (Ωcm2) was measured on the 3rd day of seeding of BeWo cell until the
confluency was reached and the resistance became constant. Mean resistance was
measured from 4-6 samples from 3 separate experiments to measure 100%
confluent cell layer which was later used in the experiments. SD represents standard
deviation of 4-6 samples.
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4.3.2.2 Effect of hepcidin treatment on iron transporter proteins and
gene expression in BeWo cells
BeWo cells were grown on inserts and after the formation of a confluent layer
they were treated with 1 µM hepcidin on either the apical or the basolateral
side for 2, 4, 6, 12, 24 and 48 hours. The time course treatment did not alter
the FPN1 protein expression as shown in Figure 4.9 (a) and (b). Similarly,
hepcidin did not change the protein expression of DMT1 in cells treated for 2
or 4 hours, Figure 4.10.
Similarly, hepcidin treatment for 2 to 48 hours did not have any effect on the
mRNA expression of TfR1, DMT1 and FPN1, Figure 4.11 (a), (b) and (c).
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Figure 4.9 Effect of hepcidin on FPN1 protein expression in BeWo cells
BeWo cells were grown on inserts and treated for 2, 4, 6, 12, 24 or 48 hours with
1µM hepcidin on the apical or the basolateral side. Western blot analysis of BeWo
cell lysates shows no difference in the treated and control cells. In (b) C represents
controlled cells treated with saline; A denotes apical treatment and B stands for
basolateral treatment. Β-actin was used as a loading control.  
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Figure 4.10 Effect of hepcidin on DMT1 expression in BeWo cells
BeWo cells were treated with hepcidin for 2 and 4 hours and DMT1 protein
expression was analysed using western blotting. The first 2 lanes show the control
cells treated with saline, lane 3 and 4 show DMT1 expression in cells treated on the
apical side and the last 2 lanes show protein expression when the cells were treated
on the basolateral side.
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Figure 4.11 Effect of hepcidin on relative mRNA expression of TFR1, DMT1 and
FPN1 in BeWo cells
BeWo cells were treated with 1µM hepcidin on the apical side for 2, 4, 6, 12,24 and
48 hours. mRNA expression of TfR1 (a) and DMT1 (b) was measured with RT-PCR
shows no difference in treated and untreated cells. (c) Hepcidin did not alter the
FPN1 mRNA expression when the cells were treated on the basolateral sides. Bars
represent mean +SEM with n=8.
(a)
(c)
(b)
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4.3.2.3 Effect of hepcidin on FPN1 expression in HEK 293 cells
To check the bioactivity of commercial and in-house hepcidin, HEK 293 (Tet-
On hFPN-GFP) and HEK 293 (Tet-Off hFPN-GFP) were treated with both
forms of hepcidin at 1µM concentration for 2 hours after turning on the GFP
expression which was measured using FACs. GFP-tagged FPN1 expression
was repressed significantly after treatment of HEK 293 Tet-On and Tet-off
cells with both commercial and in-house hepcidin, Figure 4.12 (a) and (b).
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Figure 4.12 Effect of hepcidin treatment on GFP-tagged FPN1 expression in
HEK 293 cells
HEK 293 Tet-On and Tet-Off were collected in PBS after treatment with commercial
and in-house hepcidin for 2 hours and GFP tagged FPN1 expression was measured
using FACs. Both forms of hepcidin have repressed the expression of GFP-tagged
FPN1 significantly in HEK 293 Tet-On cells (a) and HEK 293 Tet-off cells (b). Bar
graphs represents mean of 4 samples +SEM and *** shows significance at p<0.001.
***
***
***
***
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4.4 Discussion
In chapter 3 we concluded that foetal hepcidin levels were responsible for
down-regulation of placental FPN1 and possible regulation of iron transfer
across placenta by foetal liver hepcidin levels. Although regulation of foetal
liver hepcidin has not been studied but based on the evidence from studies on
adults, hepcidin is regulated by serum iron levels, hypoxia, erythropoiesis and
inflammation. Therefore, it is reasonable to assume that these same stimuli
are responsible for regulating levels of foetal hepcidin in utero. We have also
demonstrated that maternal Hfe status has a bearing on iron transport across
the placenta but this is independent of hepcidin. In order to understand the
regulation of placental iron transport by maternal hepcidin WT and Hfe KO
pregnant dams were injected with hepcidin on D14 of gestation for every 24
hours till D18 of gestation.
We have found that in WT pregnant dams, hepcidin administration has
decreased serum iron levels. This decrease has also been demonstrated in
previous studies when non-pregnant mice were injected with hepcidin (Rivera
et al. 2005; Chaston et al. 2008) and was linked with the reduction in FPN1
protein expression in the macrophages of spleen (Chaston et al. 2008).
Previous studies in non-pregnant animals have shown unaltered liver iron
stores after hepcidin injection as compared with saline injected WT mice
(Laftah et al. 2004). In parallel studies, Dr. S. Balesaria’s results were
consistent with previous findings, no change in liver iron levels observed in
WT pregnant dams after hepcidin administration. However, KO pregnant
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dams showed decreased liver iron stores after hepcidin injection but there
was no change in serum iron concentration and transferrin saturation.
In this study we have found that placental FPN1 expression in WT and Hfe
KO dams is significantly increased on hepcidin administration. These results
are in contrast to the previous studies conducted in iron transporter tissues
such as macrophages, hepatocytes and duodenal enterocytes of non-
pregnant animal models. In these rodent tissues, hepcidin was found to either
down-regulated DMT1 with no change in FPN1, FPN1 (and DMT1 expression
was not measured) (Viatte et al. 2006) or both transporters’ expression
(Harrison-Findik et al. 2006). Non-pregnant mice produced profound
hypoferremia after administration of synthetic hepcidin (Rivera et al. 2005),
demonstrating the in vivo iron-regulatory activity of the 25 amino acid hepcidin
peptide. We can speculate that in WT pregnant mice reduction in serum iron
levels due to hepcidin injection might have increased placental FPN1
expression with DMT1+IRE and ZIP14 mRNA expression in order to ensure
iron transport needed by the foetus. We can also suggest that the tissues
were not collected from the dams for analysis until 24 hours after the last
treatment of hepcidin, which could allow FPN1 transcript levels to recover and
plateau subsequent to hepcidin injection.
Placental TfR2, DMT1-IRE, FPN1 mRNA expression remained unaltered in
dams from both genotypes after hepcidin injection. Whereas, the up-
regulation of mRNA levels of DMT1+IRE and ZIP14 in the placenta of both
genotypes may indicate iron transport across placenta through alternative
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pathways as DMT1 and ZIP14 are NTBI transporters shown previously
(Gunshin et al. 1997; Gruenheid et al. 1995; Liuzzi et al. 2006). Our results,
discussed in Chapter 6, have shown increased ZIP14 expression after
provision of non-transferrin bound iron (NTBI) to BeWo cells. We have also
found that in BeWo cells DMT1+IRE expression did not alter after NTBI
supplementation so we decided to find out the localisation of DMT1 in these
cells (results shown in Chapter 5). In parallel studies S. Balesaria has shown
the same amount of liver iron concentration in the pups derived from WT and
Hfe KO dams after hepcidin administration compared with pups from saline
injected dams. These results suggest that maternal hepcidin is not disrupting
iron supply to the foetus during pregnancy.
Previous studies have demonstrated the mode of action of hepcidin by
binding to FPN1 followed by its internalisation and finally degradation
(Nemeth et al. 2004). Hepcidin seems to have a cell-specific response as
shown in previous studies where hepcidin treatment reduced FPN1
expression in macrophages (THP1 cells), erythroblast cell lines and primary
erythroblasts (K569) (Chung et al. 2009; Zhang et al. 2011). However, our
results have shown that FPN1 protein and mRNA expression did not change
in BeWo cells after hepcidin treatment for 2 to 48 hours. These results are
consistent with previous finding with no change in FPN1 expression in
duodenal enterocytes (Caco-2 cells) after hepcidin treatment as compared
with non-treated cells (Chung et al. 2009). We could speculate that hepcidin
has cell/tissue-specific effects. However, FPN1 expression was decreased
significantly when the HEK 293 cells transfected with GFP-tagged FPN1 were
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treated with both commercial and in-house hepcidin. The FPN1-GFP fusion
construct in these cells lines are localised to the cell membrane (Nemeth et al.
2004). We could speculate that FPN1 in BeWo cells was not present on the
cell membrane to act as a hepcidin receptor. Therefore, we localised FPN1 in
BeWo by immunostaining and the results are shown in Chapter 5.
In conclusion, maternal hepcidin does not affect the iron demand of the foetus
and we can suggest that the placenta develops a mechanism to continue
placental iron supply as shown by up-regulation of iron transporter mRNA
expression. When BeWo cells were treated with hepcidin, we did not see
equivalent change that was observed in placental tissue. The response of
placental tissue to dietary iron, Hfe genotype and hepcidin treatment may be
due to the presence of syncytiotrophoblasts, cytotrophoblasts, connective
tissue of villus, and endothelium of foetal capillaries. Although the mechanism
of iron transport is present in BeWo cells expressing the important iron
transporters, it seems that regulation of these transporters might be different
in these cells as compared to placenta. Therefore, the localisation of TfR1,
DMT1 and FPN1 in BeWo cells was investigated to understand the molecular
mechanism of iron transport across syncytiotrophoblasts.
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Chapter 5
Localisation of iron transporter proteins in
BeWo cells
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5.1 Introduction
As discussed in Chapter 1, the placenta is the only channel for transport of
nutrients and exchange of gases and waste products between foetus and
mother. Transport of iron is unidirectional from mother to foetus and takes
place in syncytiotrophoblasts, which form the outer layer of human
haemochorial placenta and are the only barrier between mother and placenta.
Previous studies have demonstrated that iron bound to transferrin in maternal
serum binds to TfR1 on the apical (maternal) side of syncytiotrophoblasts
(McArdle and Morgan 1982; McArdle et al. 1984). This complex is internalised
into endosomes (McArdle et al. 2003) and iron is released into the cytosol of
syncytiotrophoblasts possibly by DMT1 (Georgieff et al. 2000). The transport
of iron across the basal membrane to the foetal circulation is not clearly
understood. It is believed that iron is exported by FPN1 present on the
basolateral side of syncytiotrophoblasts (Abboud and Haile 2000; Donovan et
al. 2000). A number of studies have shown the expression of DMT1 (Georgieff
et al. 2000; Gambling et al. 2001) and FPN1 (Donovan et al. 2000; McKie et
al. 2001) on the basal membrane of syncytiotrophoblasts. Contrary to these
studies, Gruper et al (2005) have shown the co-localisation of TfR1, HFE and
DMT1 in the endosome of BeWo cells and have suggested an interaction
between TfR1 with HFE and DMT1. However, Bastin et al. (2006) have shown
localisation of HFE and FPN1 on the basal membrane and TfR1 on the apical
membrane.
140
Natural resistance-associated macrophage protein 1 (Nramp1) is a divalent
metal transporter expressed previously in phagocytes. It was hypothesized
that macrophage Nramp1 may participate in the recycling of iron acquired
from phagocytosed senescent erythrocytes (Soe-Lin et al 2009). Its presence
and role in placental cells has not been studied before. The aim of this study
is to localise the major iron transporter proteins in BeWo cells to understand
the molecular mechanism of placental iron transport.
5.2 Experimental design
BeWo cells were seeded on glass coverslips until approximately 60 to 70%
confluent. Cell were fixed with either paraformaldehyde or methanol and
incubated with primary antibodies (anti-TfR1, Nramp1, DMT1, FPN1, ZIP14,
HFE, ZO-1, Occludin, E-Cadherin) followed by incubation with fluorescent
labelled secondary antibodies. The cells were visualised using a confocal
microscope (Leica, TCS Sp5 AOBS, Leica, Mannheim, Germany or Zeiss),
Figure 5.1.
Figure 5.1 Experimental design of immunolabelling of BeWo cells
BeWo cells were seeded on coverslips and once the cells reached 60 to 70%
confluency, the cells were immunolabelled with primary and secondary antibodies
and the coverslips were mounted on glass slides to visualise under a confocal
microscope.
BeWo cells grown on
coverslips
Coverslips mounted
on glass slides
Cells incubated with
primary and flurescent
conjugated secondary
antibodies
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5.3 Results
In order to understand the localisation of important iron transporter proteins,
BeWo cells were immunolabelled for TfR1, Nramp1, DMT1, ZIP14, HFE and
FPN1. Antibodies to HFE and ZIP14 available to us did not show any
immunostaining. This could be due to antibodies being unsuitable for
immunostaining or levels being so low that they were not detectable.
5.3.1 Localisation of TfR1 in BeWo cells
BeWo cells were grown and fixed on cover slips followed by immunolabelling
for anti-TfR1 antibody (green). Cells were also incubated with AlexaFluor 594-
coupled Wheat Germ Agglutinin (WGA) (red) for 15 min prior to TfR1
immunolabelling (green). WGA recognises carbohydrates present
predominantly at the plasma membrane. xy-stacks were acquired by confocal
microscopy with the scale bar, 5 µm. Results showed that TfR1 was co-
localised with WGA on the BeWo cell membrane as shown in Figure 5.2 (c).
Due to unavailability of apical and basolateral membrane markers, we could
not confirm the presence of TfR1 on either side.
Figure 5.2 Localisation of TfR1 in BeWo cells
BeWo cells were cultured on cover slips and fixed before immunolabelling for (a)
TfR1 (green) and (b) WGA (red). xy-stacks were acquired by confocal microscope
(scale bar, 5 μm). (c) Merged image shows the co-localisation of TFR1 and WGA
(membrane marker).
(a) (b) (c)
TfR1 WGA Merged
(a) (b) (c)
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5.3.2 Co-localisation of Nramp1 with ZO-1 and Occludin in BeWo cells
Cells were seeded on glass coverslips at 70% confluence, fixed and
permeabilised before immunolabelling for Nramp1 (green). Cells were also
incubated with either AlexaFluor 594-coupled anti-ZO-1 (Figure 5.3) or anti-
Occludin in red (Figure 5.4). Zonula Occludin (ZO-1) and Occludin are tight
junction proteins present on the plasma membrane that seal together the
perimeters of polarised cells. xy- and xz-stacks were acquired by confocal
microscopy with the scale bar, 5 µm. Nramp1 in BeWo cells co-localised with
both tight junction protein markers (yellow), Figure 5.3 (c) and 5.4 (c).
Figure 5.3 Co-localisation of Nramp1 with ZO-1 in BeWo cells
BeWo cells were fixed with 4% (w/v) buffered paraformaldehyde in PBS, and
quenched with the same volume of 50 mM NH4Cl in PBS. For (a) anti-Nramp1
(green) and (b) anti-ZO-1 (red) staining, cells were fixed and permeabilised. (c) and
(c1-10) confirms sequential co-localisation of Nramp1 and ZO-1 (yellow) and (d)
shows xz-view of this co-localisation.
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(c6) (c7) (c8) (c9) (c10)
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(c6) (c7) (c8) (c9) (c10)
Nramp1 ZO-1 Merged
xz-stack
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Figure 5.4 Co-localisation of Nramp1 with Occludin in BeWo cells
BeWo cells were fixed with 4% (w/v) buffered paraformaldehyde in PBS (30 min),
and quenched with the same volume of 50 mM NH4Cl in PBS. For (a) anti-Nramp1
(green) and (b) anti-Occludin (red) staining, cells were fixed with cold methanol and
permeabilised with methanol/ethanol. (c) and (c1-10) confirms sequential co-
localisation of Nramp1 and Occludin (yellow). (d) shows xz-view of co-localisation
Nramp1 and Occludin.
(b)(a) (c)
(d)
(c1) (c2) (c3) (c4) (c5)
(c6) (c7) (c8) (c9) (c10)
Nramp1 Occludin Merged
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5.3.3 Localisation of DMT1 in BeWo cells
Cells were seeded on glass cover slips at 70% confluence, fixed and
permeabilised before immuno-labelling for anti-DMT1 (green), Figure 5.5. xy-
stack was acquired by confocal microscopy with the scale bar, 5 µm. DMT1 in
BeWo cells seemed to localise on the membrane of vesicles.
Figure 5.5 Co-localisation of DMT1 in BeWo cells
BeWo cells were seeded on cover slips with 70% confluency. Anti-DMT1 staining in
green shows the localisation of DMT1 on the membrane of vesicles in BeWo cells in
xy-view, bar scale 5 µm.
DMT1
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5.3.4 Localisation of FPN1 in BeWo cells
BeWo cells were immunolabelled with AlexaFluor 488-coupled anti-FPN1
(green) after fixation and permeabilization on cover slips. xy- and xz- views
were acquired by confocal microscopy. FPN1 seemed to localise both on the
membrane and in the cytosol of BeWo cells and the xz-view confirms its
presence in the cytosol, Figure 5.6 (b).
Figure 5.6 Localisation of FPN1 in BeWo cells
BeWo cells were seeded on cover slips with 70% confluency. (a) anti-FPN1 staining
in green shows the localisation of FPN1 on the membrane and cytosol of BeWo cells
in xy-view. (b) shows the localisation in xz-view, bar scale 5 µm.
(a)
(b)
FPN1
xz-stack
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5.4 Discussion
In the previous chapter TfR1, DMT1, FPN1 and ZIP14 mRNA expression was
quantified in placental tissues and BeWo cells. In this chapter the sub-cellular
localisation of these important iron transporters was determined to investigate
the mechanism of iron transport across syncytiotrophoblasts. Tf is recognized
by specific cell membrane receptors that act as gatekeepers responsible for
physiological iron uptake by most cell types (Richardson and Ponka, 1997).
TfR1 is an iron sensor protein, expected to sense the extracellular
concentration of holo-Tf by conventional mechanisms dependent on receptor
occupancy. As mentioned in the previous chapters, diferric-Tf is taken up from
the maternal serum via TfR1 (McArdle and Morgan 1982; McArdle et al. 1984).
Our results have shown that TfR1 is localised on the plasma membrane in
unpolarised BeWo cells. A change in placental TfR1 mRNA expression in
response to maternal Hfe status and dietary iron intake shows its role in
sensing the serum transferrin bound iron (results shown in Chapter 3).
DMT1 is a mammalian transmembrane metal-ion transporter which mediates
the transport of various divalent metal ions including Fe2+, Cd2+, Co2+, Ni2 +,
Cu2+, and Ca2+ but with its highest affinity for iron (Gunshin et al. 1997). The
data shows localisation of DMT1 inside the vesicles present in the cytoplasm of
the cells. Without any lysosomal or endosomal markers, it is difficult to identify
the vesicles. If we assume the vesicles are endosomes then this agrees with
the role of DMT1 in transporting iron from endosome into the cytoplasm
(Gruenheid et al. 1995). This finding is contrary to previous studies where
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DMT1 was shown to be localised to the basal membrane of the
syncytiotrophoblasts in human placental biopsies (Georgieff et al. 2000).
The data presented here demonstrate a strong co-localisation of Nramp1 on
the tight junction after dual staining with anti-Nramp1 and two individual tight
junction markers (ZO-1 and Occludin). Tight junctions are intracellular junctions
where the cell membranes hold the two cells together. One of their functions is
to maintain the polarity of cells. Tight junctions are the most apical structure of
the apical complex separating the border between apical and basolateral
membrane domains. Occludin was the first identified transmembrane
component of tight junctions but its function is still not understood (Guo 2003;
Niessen 2007). As Nramp1 is a transmembrane metal transporter, and its
strong co-localisation with Occludin and ZO-1 makes it easy to understand its
presence on cell junction and its involvement in intercellular iron transport but
its role is still unclear and needs further investigation.
FPN1 has cytoplasmic amino acid membrane termini and 10 to 12
transmembrane domains (Abboud and Haile 2000; McKie et al. 2000;
Donovan et al. 2000). It is an iron exporter present on the basal membrane of
absorptive intestinal enterocytes, hepatocytes, and macrophages, all of which
release iron into plasma (Abboud and Haile 2000; McKie et al. 2000; Donovan
et al. 2000). Previous studies by two independent groups have demonstrated
the localisation of FPN1 on the basolateral side of the placental
syncytiotrophoblasts in human placental sections (Abboud and Haile 2000;
Donovan et al. 2000). However, in this study FPN1 expression was identified
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both on the membrane and cytoplasm of BeWo cells. The cytoplasmic
localisation of FPN1 may suggest a role for FPN1 in iron transport from the
cytosol to the organelles.
It is important to note that the current study was conducted in unpolarised
BeWo cells in vitro because confocal imaging can be only done on clear glass
unlike inserts, therefore we can only speculate the function of these proteins
in each location. To further understand their role in placental iron transport
this study should be carried out after treating BeWo cells with hepcidin and
induction with iron deficiency, supplementation and hypoxia. Any response of
iron transporters expression after these treatments will further help us in
understanding the molecular mechanism of placental iron transport.
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Chapter 6
Is ZIP14 important in placental iron
transport?
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6.1 Introduction
In hereditary haemochromatosis, iron overload causes transferrin saturation
(TFS) resulting in an increase non-Tf-bound iron (NTBI) in serum. A number
of potential candidates involved in NTBI uptake have been identified in liver.
One such candidate is the transmembrane protein ZIP14 (Gao et al. 2008;
Liuzzi et al. 2006). Zrt-, Irt-like proteins (ZIP) are a group of protein
transporters involved in bio-metal transport into the cytosol of various cells.
Mostly they are responsible for zinc transport which is involved in normal cell
growth (Vallee and Falchuk 1993) and making of enzymes (Vallee and Auld
1990). It has been found that over-expression of HFE in HepG2 cells
decreased ZIP14 level which resulted in less NTBI uptake into the cells (Gao
et al. 2008). In a previous study performed in our group (unpublished data), it
has been shown that expression of ZIP14 varies in response to iron levels.
The role of this zinc transporter in iron homeostasis is not well understood.
The presence of ZIP14 in placenta has not been reported previously.
The aim of this study is to determine ZIP14 expression in BeWo cells and
mouse placenta and to study the regulation of ZIP14 by HFE and hepcidin.
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6.2 Experimental design
For in vitro studies BeWo cells were treated with 100µM Fe-NTA (for NTBI
supplementation), 20µM DFO (for inducing iron deficiency) or 1 µM hepcidin
and total RNA was extracted to determine gene expression of iron transporter
and storage proteins. BeWo cells that over-express HFE were cultured to
determine the ZIP14 mRNA expression.
For in vivo experiments, to study the effect of maternal Hfe on ZIP14 in
placenta, WT and Hfe KO dams were mated with HET males. From the
progeny HET pups were selected. At D18, dams were sacrificed and the
placenta placental tissues were collected from WT, Hfe KO and HET dams.
To determine the effect of foetal Hfe on ZIP14, HET dams were mated with
HET males. From the progeny, WT and Hfe KO pups were selected and their
placental and hepatic tissues were collected after the pregnant dams were
sacrificed on D18. The experimental design is explained in detail in Chapter
3.2.
For in vivo studies on the effects of hepcidin treatment, on D14 of gestation
WT and Hfe KO females were injected with either 0.15M NaCl or 10µg
hepcidin dissolved in 0.15M NaCl via the intraperitoneal route every 24 hours.
On D18, dams were sacrificed and their placenta used for total RNA
extraction. The detailed experimental design is given in Chapter 4.2.1.
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6.3 Results
6.3.1 In vitro studies
6.3.1.1 Effect of NTBI supplementation on iron transporter and storage
gene expression in BeWo cells
BeWo cells were supplemented with NTBI in the form of Fe-NTA and mRNA
expression of TfR1, ZIP14, DMT1, H-Ferritin, L-Ferritin, FPN1 and zyklopen
(Zp) was measured by RT-PCR. After iron supplementation, ZIP14 and H-
Ferritin expression were up-regulated as compared with non-
treated/controlled BeWo cells. TfR1, DMT1, FPN1 and Zp remained unaltered
after the treatment. We were not able to detect any expression for L-Ferritin in
BeWo cells, Figure 6.1.
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Figure 6.1 Effect of NTBI supplementation on iron transporter and storage gene
expression in BeWo cells
RNA was extracted from BeWo cells after incubation with 100µM Fe-NTA for 24
hours. mRNA expression of iron transporter and storage proteins were measured by
RT-PCR. ZIP14 and H-Ferritin were down-regulated. TfR1, DMT1, FPN1 and Zp
expression remained unaltered. Bar represents Mean + SEM of 4 samples and
significance difference is denoted by * with p<0.05.
*
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6.3.1.2 Effect of iron deficiency on iron transporter and storage gene
expression in BeWo cells
Iron deficiency in BeWo cells was induced by DFO and our results have shown
that TfR1 expression was up-regulated in the treated cells. In iron deficiency,
H-Ferritin gene expression was down-regulated and there was no significant
difference in the mRNA expression of ZIP14, DMT1, FPN1 and Zp, Figure 6.2.
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Figure 6.2 Effect of iron deficiency on iron transporter and storage gene
expression in BeWo cells
RNA was extracted from BeWo cells after induction of iron deficiency with 20µM DFO
for 20 hours. mRNA expression of iron transporter and storage proteins were
measured by RT-PCR. TfR1 was up-regulated after the treatment and H-Ferritin was
down-regulated. ZIP14, DMT1, FPN1 and Zp expression remained unaltered. Bar
represents Mean + SEM of 4 samples and significance difference is denoted by *
with p<0.05.
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6.3.1.3 Effect of hepcidin treatment on ZIP14 mRNA expression
BeWo cells were treated with hepcidin for 2, 4, 6, 12, 24 and 48 hours and
mRNA expression of ZIP14 was measured by RT-PCR. The treatment did not
alter the mRNA expression of ZIP14 (Figure 6.3), as was the case for other
iron transporters mRNA described shown in Chapter 4.3.2.2.
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Figure 6.3 Effect of hepcidin treatment on ZIP14 mRNA expression in BeWo
cells
BeWo cells were treated with 1 µM hepcidin for 2 to 48 hours. Total RNA was
isolated from BeWo cells and mRNA expression of ZIP14 was measured by RT-PCR
which shows that the expression was not altered by time-dependent hepcidin
treatment. Bar show mean + SEM of 4 samples.
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6.3.1.4 Comparison of mRNA levels of ZIP14 after transfection with HFE
BeWo cells stably transfected with HFE showed a reduction in the mRNA
levels of ZIP14 compared with WT BeWo cells.
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Figure 6.4 Comparison of ZIP14 mRNA levels after HFE transfection in BeWo
cells
ZIP14 mRNA expression was determined by RT-PCR and normalized to the internal
GAPDH control in WT and stably transfected BeWo cells. ZIP14 expression was
reduced significantly in the stably transfected cells. Bar graphs represent mean of 6
samples with SEM and * denotes significance difference at p<0.05.
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6.3.1.5 Effect of iron supplementation on ZIP14 mRNA expression in HFE
expressed BeWo cells
When WT and HFE transfected BeWo cells were provided NTBI in the form of
Fe-NTA, ZIP14 gene expression increased significantly, Figure 6.5 (a) and (b)
(a) (b)
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Figure 6.5 Effect of iron supplementation on ZIP14 mRNA expression
Total RNA was isolated from WT and HFE transfected BeWo cells after incubation
with100µM Fe-NTA for 24 hours. ZIP14 expression was measured by RT-PCR and
normalized to GAPDH. (a) In BeWo cells ZIP14 gene expression was increased after
uptake of NTBI (Fe-NTA). (b) Similarly, BeWo cells transfected with HFE have
increased ZIP14 expression after addition of Fe-NTA.
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6.3.2 In vivo studies
6.3.2.1 Effect of maternal Hfe and dietary iron on placental mRNA
expression of ZIP14
Maternal Hfe status did not seem to affect the mRNA expression of placental
ZIP14 when the pregnant dams were fed low or normal iron diets. When the
dams were fed a diet with high iron content, HET pups from Hfe KO dams had
significantly higher ZIP14 placental gene expression as compared with HET
pups from WT dams. Overall, the expression of the gene increased
irrespective of the genotype of the dams when fed a high iron diet, Figure 6.6.
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Figure 6.6 Effect of maternal genotype and dietary iron on placental ZIP14 gene
expression
mRNA expression of placental ZIP14 was determined by RT-PCR. Only HET pups
from HFE KO dams fed a high iron diet had significantly higher ZIP14 gene
expression as compared with HET pups from WT dams. Bar represents Mean + SEM
of 6 samples and significance difference is denoted by * with p<0.05.
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6.3.2.2 Effect of foetal Hfe and dietary iron on placental mRNA
expression of ZIP14
Foetal genotype and dietary iron of HET dams did not alter the mRNA
expression of ZIP14 in placental tissues. Overall, there was a higher trend in
the ZIP14 gene expression in Hfe KO pups from HET dams compared to
those of WT dams, but the difference did not reach significance, Figure 6.7.
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Figure 6.7 Effect of foetal genotype and dietary iron on placental ZIP14 gene
expression
The genotype of the foetus and dietary iron did not change the mRNA expression
levels of ZIP14 in the placental tissues of WT and Hfe KO pups from HET dams. Bar
graph shows mean + SEM of n=4-7.
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6.3.2.3 Effect of hepcidin on WT and Hfe KO placental ZIP14 expression
As also shown in Chapter 4, sections 4.3.1.2 and 4.3.1.4, ZIP14 expression
has increased significantly in the placenta of WT and Hfe KO dams after
hepcidin injection as compared with dams injected with saline, Figure 6.8.
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Figure 6.8 Effect of hepcidin treatment on placental ZIP14 gene expression in
WT and Hfe KO pregnant dams
ZIP14 mRNA expression was analysed by RT-PCR. Hepcidin treatment increased
the mRNA expression of ZIP14 in placenta of both WT and Hfe KO dams. Bars
denotes mean + SEM of 6 samples per group. * represents p < 0.05 and ** denotes p
< 0.001 in hepcidin injected WT and Hfe KO mice compared to saline injected
controls.
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6.4 Discussion
The developing human foetus has a huge demand for iron for its
development, requiring about 250-300 mg during gestation. Iron transport is
unidirectional from maternal to foetal blood. The placenta also functions as a
storage depot for iron. The presence of transferrin receptors on the maternal
side of the syncytiotrophoblasts plays a major role in transferrin-bound iron
transport across the placenta (Johnson et al. 1980; Galbraith et al. 1980).
Uptake of iron by placental syncytiotrophoblasts in the form of NTBI is not
known. We used BeWo cells to determine the alternative pathways of iron
uptake across syncytiotrophoblasts. These cells possess many of the key
features of placenta, including the ability to polarise and secrete placental
hormones.
Our results have shown that provision of NTBI resulted in increased mRNA
expression of ZIP14 and H-Ferritin. ZIP14, initially identified as a zinc
transporter, transfection increased NTBI uptake in HEK293, HepG2 and Sf9
insect cells (Gao et al. 2008; Luizzi et al. 2006). TfR1, DMT1, FPN1 and Zp
expression did not alter after NTBI supplementation. We propose that ZIP14
is involved in NTBI uptake in the cells and ferritin is involved in storing the
excess iron. When the cells were made iron deficient TfR1 expression was
up-regulated as was also shown in previous studies conducted in BeWo cells
(Gambling et al. 2001). However, in contrast with the TfR1 up-regulated
expression in iron deficiency, H-Ferritin expression was down-regulated,
which is in agreement with previous findings. In order to understand the role
of ZIP14 in the molecular mechanism of iron transport across placenta and its
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regulation by HFE and hepcidin, we used BeWo cells transfected with HFE.
Previous studies have shown that stable transfection of HFE in HepG2 cells
reduced iron uptake compared to that of WT cells (Luizzi et al. 2006). Stable
transfection of HFE in BeWo cells also reduced the mRNA level of ZIP14 as
compared with WT BeWo cells. When WT and HFE expressing BeWo cells
were incubated with NTBI, up-regulation of ZIP14 mRNA expression shows
that it is regulated by iron.
Our in vivo results have shown that maternal Hfe status has affected ZIP14
expression in placenta from Hfe KO dams fed a high iron diet. As discussed in
Chapter 3.3.1.7 liver iron levels were high in foetuses of Hfe KO as compared
with WT dams. This data suggests that maternal Hfe is controlling NTBI
uptake, and is diet dependent. However, foetal genotype did not seem to play
a role in NTBI transport across the placenta. Hepcidin administration did not
alter the foetal liver iron levels derived from WT or Hfe KO dams, but
increased the mRNA expression of ZIP14 in the placenta.
Future studies to elaborate the role of ZIP14 in NTBI in placental
syncytiotrophoblasts are needed.
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Chapter 7
General Discussion
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To determine the molecular mechanism of placental iron transport and its
regulation by Hfe and hepcidin, this thesis posed the following questions:
1. How does maternal Hfe regulate iron transport across placenta?
2. How does foetal Hfe regulate maternal and foetal iron homeostasis?
3. Can hepcidin regulate placental iron transport?
4. What is the molecular mechanism of iron transport from mother to the
foetus?
5. Is ZIP14 important in placental iron transport?
7.1 How does maternal Hfe regulate iron transport across placenta?
Knockout of functional maternal Hfe resulted in high iron concentration in the
circulation of mothers and increased accumulation of iron in the livers when
the dietary iron level was normal or high (Sections 3.3.1.1 and 3.3.12).
However, when the mothers were fed an iron deficient diet, the dams
maintained their body iron stores and less iron was transported to the foetus.
The direct consequence of less iron transport across the placenta was low
foetal body iron stores. Therefore to avoid the chances of iron deficiency
anaemia in pregnant mothers and neonates and low birth weights, mothers
should have good stores of iron in their livers. To further understand the
transport of iron across the placenta, we measured the placental TfR1, DMT1
and FPN1 mRNA expression and found their up-regulation in placenta of HET
pups derived from Hfe KO dams when fed normal or high iron diet. In support
of this we have shown that HET pups from Hfe KO dams have a higher iron
accumulation in their livers compared with HET pups from WT dams when the
dams were fed normal or high iron diets (Section 3.3.1.7). Overall our results
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show that adequate dietary iron during pregnancy plays an important role in
maintaining iron homeostasis in both mother and foetus. Maternal Hfe
expression is responsible for high iron in the maternal circulation and
increased transfer of iron across the placenta.
7.2 How does foetal Hfe regulate maternal and foetal iron homeostasis?
Foetal Hfe was found to play a role in controlling iron homeostasis in both
mother and foetus when the dams were fed a high iron diet. Our results have
shown that the absence of Hfe in the foetus resulted in increased iron in the
maternal circulation, high liver and spleen iron levels and more iron
accumulation in foetal liver when the HET dams were fed a high iron diet
(Sections 3.3.2.1, 3.3.2.2 and 3.3.2.6). Our data support previous studies
showing foetal hepatic iron levels regulate iron transfer from mother to foetus.
Up-regulation of DMT1+IRE expression in the placenta of Hfe KO pups from
HET dams fed high iron diet may suggest an increase in transfer of iron to the
foetus (Section 3.3.2.4). When the dietary iron intake in mother is low or
normal, foetal Hfe has no affect in the regulation of iron homeostasis in the
mother and foetus.
7.3 Can hepcidin regulate placental iron transport?
The hepcidin response is tissue or cell-specific. Our results have shown
hepcidin decreasing serum iron levels in WT pregnant dams (Section 4.3.1.1)
but the FPN1 expression in the placenta was up-regulated (Section 4.3.1.2).
BeWo cells did not respond to hepcidin treatment. The results from the dams
show that placenta plays an important role in protecting the foetus by
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continuing the supply of nutrients at any cost. However, serum iron and
transferrin saturation levels did not alter in Hfe KO pregnant dams after
hepcidin treatment. Up-regulation of ZIP14 and DMT1+IRE expression could
indicate the uptake of iron by an alternative pathway. Localisation of Nramp1
to the cell junction shows that this protein may be involved in intercellular iron
transport. FPN1 and TfR1 localisation on the membrane of BeWo cells clearly
indicate their involvement in transporting the metal. A proposed model of
regulation of placental iron transport by maternal and foetal HFE and hepcidin
iron intake is shown in Figure 7.1.
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Figure 7.1 Proposed model of regulation of placental iron transport: Role of
HFE and hepcidin.
A pregnancy signal (unknown) down-regulates hepcidin levels in liver during the last
trimester of pregnancy. This decrease results in high duodenal iron uptake and high
iron efflux from the liver into the maternal circulation. Maternal HFE can either directly
or indirectly regulate iron transport across the placenta by increasing iron in the
maternal circulation but this effect is diet dependent. The foetus regulates iron uptake
from the placenta by regulating its liver hepcidin levels which can interact with iron
exporter (FPN1). The coordinated interaction between hepcidin and FPN1 regulates
foetal iron uptake from the mother, its storage in the liver and circulation in the body.
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7.4 What is the molecular mechanism of iron transport from mother to
the foetus?
In order to understand how iron transport is regulated across the placenta, it
was crucial to determine the mechanism by which iron is transported from
mother to foetus. This study demonstrated that TfR1, an iron uptake protein,
was present on the cell membrane. DMT1 presence in the cell vesicles
indicates that this protein is involved in iron efflux from the endosome into the
cytosol of syncytiotrophoblasts as suggested before. FPN1 presence on the
BeWo cell membrane and cytosol could suggest the involvement of this
protein in transporting cytosol free iron to other organelles and efflux into
foetal circulation.
7.5 Is ZIP14 important in placental iron transport?
Up-regulation of ZIP14, an NTBI transporter, after hepcidin injection during
pregnancy indicates that this zinc transporter might be involved in NTBI iron
transport across the placenta. This was further confirmed by its up-regulation
when the BeWo cells were provided with NTBI. A proposed mechanism of
placental iron transport is shown in Figure 7.2.
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Figure 7.2 Proposed mechanism of placental iron transport
From the maternal circulation diferric-transferrin binds to TfR1 followed by its
internalisation in the syncytiotrophoblasts. How iron enters the cytosol of the cells
remains a mystery. In alternative pathway, iron as NTBI is taken up by ZIP14. Iron
can be transported to other organelles or to be stored as ferritin, probably by FPN1.
Iron is effluxed into the foetal circulation via FPN1 after oxidation by Zp.
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7.6 Future work
In the present study, it was shown that hepcidin did not affect the iron
transporter gene expression in BeWo cells. How hepcidin regulates iron
uptake in BeWo cells is unknown. Therefore, further studies investigating the
effect of hepcidin on iron uptake need to be performed. This will be done by
growing BeWo cells on inserts to polarise them into apical (maternal side) and
basolateral (foetal side) sides. The cells will be incubated with hepcidin from
either maternal or foetal side and iron uptake using transferring-bound Fe55 or
Fe59 will be measured by scintillation counting.
Localisation of DMT1 was unusual in BeWo cells. The role of DMT1 in
placental iron transport in not clearly understood. To further understand the
molecular mechanism of iron transport across placenta, the main iron
transporter proteins (TfR1, DMT1, FPN1 and Hfe) will be localised in mice
placental tissue. These proteins will be localised in BeWo cells after making
them iron deficient, iron supplemented or hypoxic to determine their
regulation.
Our results showed the presence of ZIP14 in mice placental tissues and
BeWo cells. The localisation of ZIP14 in placental syncytiotrophoblasts is not
known. Involvement of this zinc transporter in iron transport and regulation by
HFE is not clearly understood. Therefore, in future studies, ZIP14 will be
localised in BeWo cells or placental tissues by immunostaining using
appropriate antibodies. HFE over-expressed BeWo cells will be provided with
Fe55 or Fe59 labelled NTBI to measure iron uptake involving ZIP14. Over
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expression of HFE resulted in decreased ZIP14 expression so we expect
decreased NTBI uptake in BeWo cells.
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Appendix
Data presented in Figure 3.3 (a)
Serum iron levels (µg/dL) of WT pregnant dams
Diet n Mean SD SEM
p value with
50ppm
p value with
150ppm
12.5ppm 4 39.87 6.22 3.11 0.1031 0.0124
50ppm 5 72.16 33.55 15.00 0.2075
150ppm 4 104.42 36.03 18.02
Serum iron levels (µg/dL) of KO pregnant dams
Diet n Mean SD SEM
p value with
50ppm
p value with
150ppm
12.5ppm 2 38.79 30.48 21.55 0.1059 0.0002
50ppm 4 108.82 41.27 20.63 0.0065
150ppm 5 181.53 11.14 4.98
Data presented in Figure 3.3 (b)
Transferrin saturation (%) of WT pregnant dams
Diet n Mean SD SEM
p value with
50ppm
p value with
150ppm
12.5ppm 4 14.13 1.86 0.93 0.2608 0.0134
50ppm 5 20.68 6.26 3.13 0.9638
150ppm 4 24.41 4.10 2.40
Tranferrin saturation (%) of KO pregnant dams
Diet n Mean SD SEM
p value with
50ppm
p value with
150ppm
12.5ppm 2 38.67 18.34 10.59 0.7032 0.6491
50ppm 3 39.00 7.03 4.06 0.01
150ppm 5 42.34 4.34 1.94
Data presented in Figure 3.12 (a)
Serum iron levels (µg/dL) of HET pregnant dams
Diet n Mean SD SEM
p value with
50ppm
p value with
150ppm
12.5ppm 4 45.26 32.11 16.06 0.1425 0.0294
50ppm 5 77.25 26.18 11.71 0.2142
150ppm 5 100.80 28.94 12.94
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Data Presented in Figure 3.12 (b)
Transferrin saturation (%) of HET pregnant dams
Diet n Mean SD SEM
p value with
50ppm
p value with
150ppm
12.5ppm 4 28.00 14.26 7.13 0.6348 0.2853
50ppm 5 24.59 5.53 2.47 0.0192
150ppm 5 42.34 4.34 1.94
